1
|
van der Ark-Vonk EM, Puijk MV, Pasterkamp G, van der Laan SW. The Effects of FABP4 on Cardiovascular Disease in the Aging Population. Curr Atheroscler Rep 2024; 26:163-175. [PMID: 38698167 PMCID: PMC11087245 DOI: 10.1007/s11883-024-01196-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/05/2024] [Indexed: 05/05/2024]
Abstract
PURPOSE OF REVIEW Fatty acid-binding protein 4 (FABP4) plays a role in lipid metabolism and cardiovascular health. In this paper, we cover FABP4 biology, its implications in atherosclerosis from observational studies, genetic factors affecting FABP4 serum levels, and ongoing drug development to target FABP4 and offer insights into future FABP4 research. RECENT FINDINGS FABP4 impacts cells through JAK2/STAT2 and c-kit pathways, increasing inflammatory and adhesion-related proteins. In addition, FABP4 induces angiogenesis and vascular smooth muscle cell proliferation and migration. FABP4 is established as a reliable predictive biomarker for cardiovascular disease in specific at-risk groups. Genetic studies robustly link PPARG and FABP4 variants to FABP4 serum levels. Considering the potential effects on atherosclerotic lesion development, drug discovery programs have been initiated in search for potent inhibitors of FABP4. Elevated FABP4 levels indicate an increased cardiovascular risk and is causally related to acceleration of atherosclerotic disease, However, clinical trials for FABP4 inhibition are lacking, possibly due to concerns about available compounds' side effects. Further research on FABP4 genetics and its putative causal role in cardiovascular disease is needed, particularly in aging subgroups.
Collapse
Affiliation(s)
- Ellen M van der Ark-Vonk
- Central Diagnostics Laboratory, Division Laboratory, Pharmacy, and Biomedical Genetics, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands
| | - Mike V Puijk
- Central Diagnostics Laboratory, Division Laboratory, Pharmacy, and Biomedical Genetics, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands
| | - Gerard Pasterkamp
- Central Diagnostics Laboratory, Division Laboratory, Pharmacy, and Biomedical Genetics, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands
| | - Sander W van der Laan
- Central Diagnostics Laboratory, Division Laboratory, Pharmacy, and Biomedical Genetics, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands.
| |
Collapse
|
2
|
Liu L, Shi Z, Ji X, Zhang W, Luan J, Zahr T, Qiang L. Adipokines, adiposity, and atherosclerosis. Cell Mol Life Sci 2022; 79:272. [PMID: 35503385 PMCID: PMC11073100 DOI: 10.1007/s00018-022-04286-2] [Citation(s) in RCA: 43] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Revised: 03/11/2022] [Accepted: 04/03/2022] [Indexed: 12/12/2022]
Abstract
Characterized by a surplus of whole-body adiposity, obesity is strongly associated with the prognosis of atherosclerosis, a hallmark of coronary artery disease (CAD) and the major contributor to cardiovascular disease (CVD) mortality. Adipose tissue serves a primary role as a lipid-storage organ, secreting cytokines known as adipokines that affect whole-body metabolism, inflammation, and endocrine functions. Emerging evidence suggests that adipokines can play important roles in atherosclerosis development, progression, as well as regression. Here, we review the versatile functions of various adipokines in atherosclerosis and divide these respective functions into three major groups: protective, deteriorative, and undefined. The protective adipokines represented here are adiponectin, fibroblast growth factor 21 (FGF-21), C1q tumor necrosis factor-related protein 9 (CTRP9), and progranulin, while the deteriorative adipokines listed include leptin, chemerin, resistin, Interleukin- 6 (IL-6), and more, with additional adipokines that have unclear roles denoted as undefined adipokines. Comprehensively categorizing adipokines in the context of atherosclerosis can help elucidate the various pathways involved and potentially pave novel therapeutic approaches to treat CVDs.
Collapse
Affiliation(s)
- Longhua Liu
- School of Kinesiology, Shanghai University of Sport, Shanghai, People's Republic of China.
| | - Zunhan Shi
- School of Kinesiology, Shanghai University of Sport, Shanghai, People's Republic of China
| | - Xiaohui Ji
- School of Kinesiology, Shanghai University of Sport, Shanghai, People's Republic of China
| | - Wenqian Zhang
- School of Kinesiology, Shanghai University of Sport, Shanghai, People's Republic of China
| | - Jinwen Luan
- School of Kinesiology, Shanghai University of Sport, Shanghai, People's Republic of China
| | - Tarik Zahr
- Department of Pharmacology, Columbia University, New York, NY, USA
| | - Li Qiang
- Department of Pathology and Cellular Biology and Naomi Berrie Diabetes Center, Columbia University, New York, NY, USA.
| |
Collapse
|
3
|
Batty MJ, Chabrier G, Sheridan A, Gage MC. Metabolic Hormones Modulate Macrophage Inflammatory Responses. Cancers (Basel) 2021; 13:cancers13184661. [PMID: 34572888 PMCID: PMC8467249 DOI: 10.3390/cancers13184661] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2021] [Revised: 08/31/2021] [Accepted: 09/13/2021] [Indexed: 12/17/2022] Open
Abstract
Simple Summary Macrophages are a type of immune cell which play an important role in the development of cancer. Obesity increases the risk of cancer and obesity also causes disruption to the normal levels of hormones that are produced to coordinate metabolism. Recent research now shows that these metabolic hormones also play important roles in macrophage immune responses and so through macrophages, disrupted metabolic hormone levels may promote cancer. This review article aims to highlight and summarise these recent findings so that the scientific community may better understand how important this new area of research is, and how these findings can be capitalised on for future scientific studies. Abstract Macrophages are phagocytotic leukocytes that play an important role in the innate immune response and have established roles in metabolic diseases and cancer progression. Increased adiposity in obese individuals leads to dysregulation of many hormones including those whose functions are to coordinate metabolism. Recent evidence suggests additional roles of these metabolic hormones in modulating macrophage inflammatory responses. In this review, we highlight key metabolic hormones and summarise their influence on the inflammatory response of macrophages and consider how, in turn, these hormones may influence the development of different cancer types through the modulation of macrophage functions.
Collapse
|
4
|
A-FABP in Metabolic Diseases and the Therapeutic Implications: An Update. Int J Mol Sci 2021; 22:ijms22179386. [PMID: 34502295 PMCID: PMC8456319 DOI: 10.3390/ijms22179386] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Revised: 08/27/2021] [Accepted: 08/27/2021] [Indexed: 12/11/2022] Open
Abstract
Adipocyte fatty acid-binding protein (A-FABP), which is also known as ap2 or FABP4, is a fatty acid chaperone that has been further defined as a fat-derived hormone. It regulates lipid homeostasis and is a key mediator of inflammation. Circulating levels of A-FABP are closely associated with metabolic syndrome and cardiometabolic diseases with imminent diagnostic and prognostic significance. Numerous animal studies have elucidated the potential underlying mechanisms involving A-FABP in these diseases. Recent studies demonstrated its physiological role in the regulation of adaptive thermogenesis and its pathological roles in ischemic stroke and liver fibrosis. Due to its implication in various diseases, A-FABP has become a promising target for the development of small molecule inhibitors and neutralizing antibodies for disease treatment. This review summarizes the clinical and animal findings of A-FABP in the pathogenesis of cardio-metabolic diseases in recent years. The underlying mechanism and its therapeutic implications are also highlighted.
Collapse
|
5
|
Ong KL, Wu L, Januszewski AS, O'Connell RL, Xu A, Rye KA, Ma RCW, Li H, Jenkins AJ, Jia W, Keech AC. Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study. Diabetes Res Clin Pract 2020; 169:108450. [PMID: 32949655 DOI: 10.1016/j.diabres.2020.108450] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/09/2020] [Revised: 07/24/2020] [Accepted: 09/14/2020] [Indexed: 10/23/2022]
Abstract
AIMS To investigate determinants of circulating levels of adipocyte-fatty acid binding protein (A-FABP) and lipocalin-2 (LCN2), their relationships with cardiovascular disease (CVD) and microvascular events, and effects of fenofibrate in type 2 diabetes (T2D). METHODS A-FABP and LCN2 were quantified in baseline plasma from 2000 T2D adults in a Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial sub-study and correlates thereof determined. In a subset (n = 200) adipokines were also measured on-trial. RESULTS Female sex, older age, higher body mass index (BMI), HbA1c, insulin resistance index, triglycerides, plasma creatinine and homocysteine, shorter diabetes duration, and use of oral hypoglycaemic agents alone were independent determinants of higher A-FABP. Higher BMI, fibrinogen and homocysteine, Caucasian race, and lower fasting glucose, HDL-cholesterol, apolipoprotein A-II and estimated glomerular filtration rate were independent predictors of higher LCN2 levels. Baseline A-FABP and LCN2 levels were associated with multiple new CVD and microvascular events over 5-years, though significance was lost after risk factor adjustment. Fenofibrate increased A-FABP but did not change LCN2 levels. CONCLUSIONS Baseline plasma A-FABP and LCN2 levels were associated with concurrent CVD risk factors, and on-trial chronic complications, likely mediated via traditional risk factors. Fenofibrate increased A-FABP modestly but did not affect LCN2 levels. CLINICAL TRIAL REGISTRATION ISRCTN 64783481.
Collapse
Affiliation(s)
- Kwok-Leung Ong
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Lipid Research Group, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia
| | - Liang Wu
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Endocrinology and Metabolism, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center of Diabetes, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
| | | | - Rachel L O'Connell
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
| | - Aimin Xu
- Department of Medicine, University of Hong Kong, Hong Kong; State Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, Hong Kong
| | - Kerry-Anne Rye
- Lipid Research Group, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia
| | - Ronald C W Ma
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong
| | - Huating Li
- Department of Endocrinology and Metabolism, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center of Diabetes, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
| | - Alicia J Jenkins
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
| | - Weiping Jia
- Department of Endocrinology and Metabolism, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center of Diabetes, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
| | - Anthony C Keech
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
| |
Collapse
|
6
|
Gormez S, Erdim R, Akan G, Caynak B, Duran C, Gunay D, Sozer V, Atalar F. Relationships between visceral/subcutaneous adipose tissue FABP4 expression and coronary atherosclerosis in patients with metabolic syndrome. Cardiovasc Pathol 2019; 46:107192. [PMID: 31927390 DOI: 10.1016/j.carpath.2019.107192] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/06/2019] [Revised: 10/17/2019] [Accepted: 11/28/2019] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND Cytoplasmic fatty acid-binding proteins facilitate the transport of lipids to specific compartments in cells. Fatty acid-binding protein 4 (FABP4), also known as aP2 or A-FABP, plays a key role in the development of atherosclerosis, insulin resistance, obesity, and metabolic syndrome (MS). The FABP4 polymorphisms are associated with protein expression changes in vitro and metabolic and vascular alterations in vivo. The aim of this study was to investigate the association between FABP4 messenger ribonucleic acid (mRNA) expression levels in epicardial (EAT), pericardial (PAT), and subcutaneous adipose tissues (SAT), and the extent of coronary atherosclerosis in coronary artery disease (CAD) patients with MS. Furthermore, the relationship between the extent of coronary atherosclerosis and epicardial adipose tissue volume (EATV) and FABP4 gene variations was evaluated. PATIENTS AND METHODS A total of 37 patients undergoing coronary artery bypass grafting because of CAD (MS CAD group) and 23 non-MS patients undergoing heart valve surgery (control group) were included. Coronary angiography was performed for all patients and the extent of coronary atherosclerosis was assessed using the Sullivan's scoring system. The mRNA expression levels of FABP4 gene in EAT, PAT, and SAT, and FABP4 polymorphisms were analyzed using the quantitative real-time polymerase chain reaction (qRT-PCR). RESULTS An increased FABP4 expression was observed in EAT and PAT of MS CAD group compared to controls. In the MS CAD group, FABP4 mRNA expression levels in EAT was 2.8-fold higher compared to PAT. The expression of FABP4 in EAT was positively correlated with the extent of atherosclerosis and EATV in MS CAD group (r = 0.588, P= 0.001, r = 0.174, P = 0.001, respectively). There were no correlations between PAT and SAT versus the extent of atherosclerosis and EATV. The FABP4 EAT mRNA expression levels were found to significantly increase in mutant allele carriers of rs1054135, whereas they significantly decreased in mutant allele carriers of rs77878271 (T-87C) in MS CAD group (P < 0.05). The extent of atherosclerosis was also found to be significantly associated with rs1054135 (P < 0.05). A cut-off point of 57.5 cm3 EATV was used indicating the presence of CAD with a significant area under the curve of 0.783%, 98% sensitivity, and 100% specificity (95% CI 0.620-0.880; P < 0.05). CONCLUSIONS Our study results suggest that FABP4 expression in EAT is strongly associated with the extent of atherosclerosis and EATV in MS CAD patients.
Collapse
Affiliation(s)
- Selcuk Gormez
- Department of Cardiology, Acibadem Mehmet Ali Aydinlar University, Faculty of Medicine, Istanbul, Turkey
| | - Refik Erdim
- Institute of Health Sciences, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey
| | - Gokce Akan
- MUHAS Genetics Laboratory, MUHAS, Muhimbili University of Health and Allied Sciences, Dar Es Salaam, Tanzania
| | - Barıs Caynak
- Department of Cardiovascular Surgery, Istanbul Bilim University, Istanbul, Turkey
| | - Cihan Duran
- Department of Radiology, Istanbul Bilim University, Istanbul, Turkey
| | - Demet Gunay
- Sisli Florence Nightingale Hospital, Department of Biochemistry, Istanbul, Turkey
| | - Volkan Sozer
- Department of Biochemistry, Yildiz Technical University, Istanbul, Turkey
| | - Fatmahan Atalar
- Department of Medical Genetics, Child Health Institute, Istanbul University, Istanbul, Turkey.
| |
Collapse
|
7
|
Wang L, Zhu S, Zhao Q, Huang B, Lv L, Liu G, Li Z, Zhao H, Han H, Dong H. Effects of host fatty acid-binding protein 4 on Eimeria tenella sporozoites invasion of cells. Parasitol Res 2019; 118:1919-1926. [PMID: 31069534 DOI: 10.1007/s00436-019-06321-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2019] [Accepted: 04/09/2019] [Indexed: 12/16/2022]
Abstract
In our previous study, proteomics analyses of host cells infected with Eimeria tenella sporozoites coupled with isobaric tags for relative and absolute quantitation, identified several host proteins related to Eimeria invasion. In this study, A 458-bp Gallus gallus fatty acid-binding protein 4 (FABP4) gene was cloned and subcloned to pET-28c(+) vector to construct the prokaryotic recombinant expression plasmid pET-28c(+)-FABP4. The 18.5 kDa recombinant FABP4 protein (rFABP4) was expressed and identified by western blotting. Expression of FABP4 in E. tenella sporozoite-infected DF-1 cells was downregulated significantly than in non-infected cells detected by western blotting and immunohistochemistry. The antibody inhibition assay showed that antibodies against FABP4 at 50, 100, 200, 300, and 400 μg/mL had no significant effect on sporozoite invasion. BMS-309403 and transforming growth factor-β3 (TGF-β3) was used to inhibit and improve the expression of FABP4 in DF-1 cells, respectively, and their effect on the sporozoite invasion of cells was detected by flow cytometry. Sporozoite invasion rate in the BMS-309403-treated group was not significantly affected; however, the invasion rate in the TGF-β3-treated group declined significantly. These results show that host FABP4 plays a negative role in Eimeria invasion. However, further studies are needed to elucidate the exact mechanism of how FABP4 negatively regulates Eimeria invasion.
Collapse
Affiliation(s)
- Lu Wang
- Key Laboratory of Animal Parasitology of Ministry of Agriculture, Shanghai Veterinary Research Institute, CAAS, Shanghai, 200241, China
| | - Shunhai Zhu
- Key Laboratory of Animal Parasitology of Ministry of Agriculture, Shanghai Veterinary Research Institute, CAAS, Shanghai, 200241, China
| | - Qiping Zhao
- Key Laboratory of Animal Parasitology of Ministry of Agriculture, Shanghai Veterinary Research Institute, CAAS, Shanghai, 200241, China
| | - Bing Huang
- Key Laboratory of Animal Parasitology of Ministry of Agriculture, Shanghai Veterinary Research Institute, CAAS, Shanghai, 200241, China
| | - Ling Lv
- Key Laboratory of Animal Parasitology of Ministry of Agriculture, Shanghai Veterinary Research Institute, CAAS, Shanghai, 200241, China
| | - Guiling Liu
- Key Laboratory of Animal Parasitology of Ministry of Agriculture, Shanghai Veterinary Research Institute, CAAS, Shanghai, 200241, China.,College of Life and Environment Sciences, Shanghai Normal University, Shanghai, 200234, China
| | - Zhihang Li
- Key Laboratory of Animal Parasitology of Ministry of Agriculture, Shanghai Veterinary Research Institute, CAAS, Shanghai, 200241, China.,College of Life and Environment Sciences, Shanghai Normal University, Shanghai, 200234, China
| | - Huanzhi Zhao
- Key Laboratory of Animal Parasitology of Ministry of Agriculture, Shanghai Veterinary Research Institute, CAAS, Shanghai, 200241, China
| | - Hongyu Han
- Key Laboratory of Animal Parasitology of Ministry of Agriculture, Shanghai Veterinary Research Institute, CAAS, Shanghai, 200241, China
| | - Hui Dong
- Key Laboratory of Animal Parasitology of Ministry of Agriculture, Shanghai Veterinary Research Institute, CAAS, Shanghai, 200241, China.
| |
Collapse
|
8
|
Graupera I, Coll M, Pose E, Elia C, Piano S, Solà E, Blaya D, Huelin P, Solé C, Moreira R, de Prada G, Fabrellas N, Juanola A, Morales-Ruiz M, Sancho-Bru P, Villanueva C, Ginès P. Adipocyte Fatty-Acid Binding Protein is Overexpressed in Cirrhosis and Correlates with Clinical Outcomes. Sci Rep 2017; 7:1829. [PMID: 28500294 PMCID: PMC5431836 DOI: 10.1038/s41598-017-01709-0] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2017] [Accepted: 04/03/2017] [Indexed: 12/20/2022] Open
Abstract
Fatty-acid-binding proteins (FABPs) are small intracellular proteins that coordinate lipid-mediated processes by targeting metabolic and immune response pathways. The aim of the study was to investigate plasma FABPs levels and their relationship with clinical outcomes in cirrhosis. Plasma levels of L-FABP1(liver and kidney), I-FABP2(intestine), and A-FABP4(adipocyte and macrophages) were measured in 274 patients with decompensated cirrhosis. Hepatic gene expression of FABPs was assessed in liver biopsies from patients with decompensated cirrhosis and in liver cell types from mice with cirrhosis. Immunohistochemistry of A-FABP4 in human liver biopsy was also performed. Plasma levels of FABPs were increased in patients with decompensated cirrhosis compared to those of healthy subjects (L-FABP1: 25 (17–39) vs 10 (9–17) ng/mL p = 0.001, I-FABP2: 1.1 (0.5–2.1) vs 0.6 (0.4–1) ng/mL p = 0.04 and A-FABP4: 37 (20–68) vs 16 (11–33) ng/mL p = 0.002), respectively. Increased A-FABP4 levels were associated with complications of cirrhosis, acute-on-chronic liver failure and poor survival. Hepatic A-FABP4 gene expression was upregulated in decompensated cirrhosis. Macrophages were the main liver cell that over-expressed A-FABP4 in experimental cirrhosis and increased A-FABP4 was found in macrophages of human biopsies by immunohistochemistry. A-FABP4 levels are increased in decompensated cirrhosis and correlate with poor outcomes. Liver macrophages appear to be the main source of A-FABP4 in decompensated cirrhosis.
Collapse
Affiliation(s)
- Isabel Graupera
- Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
| | - Mar Coll
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
| | - Elisa Pose
- Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - Chiara Elia
- Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain
| | - Salvatore Piano
- Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain
| | - Elsa Solà
- Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain.,School of Medicine and Health Sciences Center, University of Barcelona, Barcelona, Spain
| | - Delia Blaya
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - Patricia Huelin
- Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
| | - Cristina Solé
- Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
| | - Rebeca Moreira
- Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
| | - Gloria de Prada
- Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain
| | - Núria Fabrellas
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.,School of Medicine and Health Sciences Center, University of Barcelona, Barcelona, Spain
| | - Adrià Juanola
- Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain
| | - Manuel Morales-Ruiz
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain.,Biochemistry and Molecular Genetics Department. Hospital Clínic, Department of Biomedicine-Biochemistry Unit, School of Medicine University of Barcelona, Barcelona, Spain
| | - Pau Sancho-Bru
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
| | - Càndid Villanueva
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain.,Gastroenterology department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Pere Ginès
- Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain. .,Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain. .,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain. .,School of Medicine and Health Sciences Center, University of Barcelona, Barcelona, Spain.
| |
Collapse
|
9
|
Nicholas DA, Zhang K, Hung C, Glasgow S, Aruni AW, Unternaehrer J, Payne KJ, Langridge WHR, De Leon M. Palmitic acid is a toll-like receptor 4 ligand that induces human dendritic cell secretion of IL-1β. PLoS One 2017; 12:e0176793. [PMID: 28463985 PMCID: PMC5413048 DOI: 10.1371/journal.pone.0176793] [Citation(s) in RCA: 69] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2017] [Accepted: 04/17/2017] [Indexed: 01/22/2023] Open
Abstract
Palmitic acid (PA) and other saturated fatty acids are known to stimulate pro-inflammatory responses in human immune cells via Toll-like receptor 4 (TLR4). However, the molecular mechanism responsible for fatty acid stimulation of TLR4 remains unknown. Here, we demonstrate that PA functions as a ligand for TLR4 on human monocyte derived dendritic cells (MoDCs). Hydrophobicity protein modeling indicated PA can associate with the hydrophobic binding pocket of TLR4 adaptor protein MD-2. Isothermal titration calorimetry quantified heat absorption that occurred during PA titration into TLR4/MD2, indicating that PA binds to TLR4/MD2. Treatment of human MoDCs with PA resulted in endocytosis of TLR4, further supporting the function of PA as a TLR4 agonist. In addition, PA stimulated DC maturation and activation based on the upregulation of DC costimulatory factors CD86 and CD83. Further experiments showed that PA induced TLR4 dependent secretion of the pro-inflammatory cytokine IL-1β. Lastly, our experimental data show that PA stimulation of NF-κB canonical pathway activation is regulated by TLR4 signaling and that reactive oxygen species may be important in upregulating this pro-inflammatory response. Our experiments demonstrate for the first time that PA activation of TLR4 occurs in response to direct molecular interactions between PA and MD-2. In summary, our findings suggest a likely molecular mechanism for PA induction of pro-inflammatory immune responses in human dendritic cells expressing TLR4.
Collapse
Affiliation(s)
- Dequina A. Nicholas
- Center for Health Disparities and Molecular Medicine, Loma Linda University School of Medicine, Loma Linda, California, United States of America
- Division of Biochemistry, Department of Basic Sciences, Loma Linda University School Medicine, Loma Linda, California, United States of America
| | - Kangling Zhang
- Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas, United States of America
| | - Christopher Hung
- Center for Health Disparities and Molecular Medicine, Loma Linda University School of Medicine, Loma Linda, California, United States of America
- Division of Biochemistry, Department of Basic Sciences, Loma Linda University School Medicine, Loma Linda, California, United States of America
| | - Shane Glasgow
- Center for Health Disparities and Molecular Medicine, Loma Linda University School of Medicine, Loma Linda, California, United States of America
- Division of Biochemistry, Department of Basic Sciences, Loma Linda University School Medicine, Loma Linda, California, United States of America
| | - Aruni Wilson Aruni
- Department of Basic Sciences, Division of Microbiology and Molecular Genetics, Loma Linda University School Medicine, Loma Linda, California, United States of America
| | - Juli Unternaehrer
- Center for Health Disparities and Molecular Medicine, Loma Linda University School of Medicine, Loma Linda, California, United States of America
- Division of Biochemistry, Department of Basic Sciences, Loma Linda University School Medicine, Loma Linda, California, United States of America
| | - Kimberly J. Payne
- Center for Health Disparities and Molecular Medicine, Loma Linda University School of Medicine, Loma Linda, California, United States of America
- Department of Anatomy and Physiology, Loma Linda University School Medicine, Loma Linda, California, United States of America
| | - William H. R. Langridge
- Center for Health Disparities and Molecular Medicine, Loma Linda University School of Medicine, Loma Linda, California, United States of America
- Division of Biochemistry, Department of Basic Sciences, Loma Linda University School Medicine, Loma Linda, California, United States of America
| | - Marino De Leon
- Center for Health Disparities and Molecular Medicine, Loma Linda University School of Medicine, Loma Linda, California, United States of America
- Department of Basic Sciences, Division of Physiology, Loma Linda University School Medicine, Loma Linda, California, United States of America
| |
Collapse
|
10
|
Alaarg A, Zheng KH, van der Valk FM, da Silva AE, Versloot M, van Ufford LCQ, Schulte DM, Storm G, Metselaar JM, Stroes ESG, Hamers AAJ. Multiple pathway assessment to predict anti-atherogenic efficacy of drugs targeting macrophages in atherosclerotic plaques. Vascul Pharmacol 2016; 82:51-9. [PMID: 27189780 DOI: 10.1016/j.vph.2016.04.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2015] [Revised: 03/26/2016] [Accepted: 04/01/2016] [Indexed: 12/14/2022]
Abstract
BACKGROUND Macrophages play a central role in atherosclerosis development and progression, hence, targeting macrophage activity is considered an attractive therapeutic. Recently, we documented nanomedicinal delivery of the anti-inflammatory compound prednisolone to atherosclerotic plaque macrophages in patients, which did however not translate into therapeutic efficacy. This unanticipated finding calls for in-depth screening of drugs intended for targeting plaque macrophages. METHODS AND RESULTS We evaluated the effect of several candidate drugs on macrophage activity, rating overall performance with respect to changes in cytokine release, oxidative stress, lipid handling, endoplasmic reticulum (ER) stress, and proliferation of macrophages. Using this in vitro approach, we observed that the anti-inflammatory effect of prednisolone was counterbalanced by multiple adverse effects on other key pathways. Conversely, pterostilbene, T0901317 and simvastatin had an overall anti-atherogenic effect on multiple pathways, suggesting their potential for liposomal delivery. CONCLUSION This dedicated assay setup provides a framework for high-throughput assessment. Further in vivo studies are warranted to determine the predictive value of this macrophage-based screening approach and its potential value in nanomedicinal drug development for cardiovascular patients.
Collapse
Affiliation(s)
- Amr Alaarg
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands; Department of Biomaterials Science and Technology, Targeted Therapeutics section, MIRA Institute, University of Twente, Enschede, The Netherlands.
| | - Kang He Zheng
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
| | - Fleur M van der Valk
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
| | - Acarilia Eduardo da Silva
- Department of Biomaterials Science and Technology, Targeted Therapeutics section, MIRA Institute, University of Twente, Enschede, The Netherlands.
| | - Miranda Versloot
- Department of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
| | - Linda C Quarles van Ufford
- Medicinal Chemistry & Chemical Biology - Biomolecular Analysis, Department of Pharmaceutical Sciences, Utrecht University, The Netherlands.
| | - Dominik M Schulte
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Internal Medicine I, UKSH, 24105 Kiel, Germany.
| | - Gert Storm
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands; Department of Biomaterials Science and Technology, Targeted Therapeutics section, MIRA Institute, University of Twente, Enschede, The Netherlands
| | - Josbert M Metselaar
- Department of Biomaterials Science and Technology, Targeted Therapeutics section, MIRA Institute, University of Twente, Enschede, The Netherlands; Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, Germany.
| | - Erik S G Stroes
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
| | - Anouk A J Hamers
- Department of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
| |
Collapse
|
11
|
Burak MF, Inouye KE, White A, Lee A, Tuncman G, Calay ES, Sekiya M, Tirosh A, Eguchi K, Birrane G, Lightwood D, Howells L, Odede G, Hailu H, West S, Garlish R, Neale H, Doyle C, Moore A, Hotamisligil GS. Development of a therapeutic monoclonal antibody that targets secreted fatty acid–binding protein aP2 to treat type 2 diabetes. Sci Transl Med 2015; 7:319ra205. [DOI: 10.1126/scitranslmed.aac6336] [Citation(s) in RCA: 59] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2015] [Accepted: 11/04/2015] [Indexed: 12/13/2022]
|
12
|
Abstract
Intracellular and extracellular interactions with proteins enables the functional and mechanistic diversity of lipids. Fatty acid-binding proteins (FABPs) were originally described as intracellular proteins that can affect lipid fluxes, metabolism and signalling within cells. As the functions of this protein family have been further elucidated, it has become evident that they are critical mediators of metabolism and inflammatory processes, both locally and systemically, and therefore are potential therapeutic targets for immunometabolic diseases. In particular, genetic deficiency and small molecule-mediated inhibition of FABP4 (also known as aP2) and FABP5 can potently improve glucose homeostasis and reduce atherosclerosis in mouse models. Further research has shown that in addition to their intracellular roles, some FABPs are found outside the cells, and FABP4 undergoes regulated, vesicular secretion. The circulating form of FABP4 has crucial hormonal functions in systemic metabolism. In this Review we discuss the roles and regulation of both intracellular and extracellular FABP actions, highlighting new insights that might direct drug discovery efforts and opportunities for management of chronic metabolic diseases.
Collapse
Affiliation(s)
- Gökhan S Hotamisligil
- Department of Genetics and Complex Diseases and Sabri Ülker Center, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA
| | - David A Bernlohr
- Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, 321 Church Street SE, Minneapolis, MN 55455, USA
| |
Collapse
|
13
|
Zhu Q, Jin Y, Wang P, Wang H, Lu B, Wang Z, Dong M. Expression and function of fatty acid-binding protein 4 in epithelial cell of uterine endometrium. Cell Biol Int 2015; 39:540-7. [PMID: 25572488 DOI: 10.1002/cbin.10429] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2014] [Accepted: 12/19/2014] [Indexed: 12/28/2022]
Abstract
The aims of this study were to delineate the expression of fatty-acid binding protein (FABP) 4 in human uterine endometrium and its function in the regulation of proliferation, migration and invasion of epithelial cells. Immunohistochenistry, immunofluorence and Western blotting were used to determine the expression and cellular localization of FABP4 in endometrium and endometrial epithelial cell lines. Interference of small ribonuclear acid (siRNA) and specific FABP4 inhibitor were used to inhibit FABP4. The proliferation, migration and invasion of epithelial cells were evaluated with CCK-8 assay, wound-healing test and transwell analysis respectively. We found that FABP4 was expressed by epithelial cells of proliferative endometrium and epithelial and stromal cells of secrectory endometrium. Epithelial cell lines Ishikawa and RL-952 expressed FABP4 and this expression was decreased by FABP4 siRNA. FABP4 siRNA and specific FABP4 inhibition significantly decreased the proliferation, migration and invasion of epithelial cell lines. We concluded that FABP4 is functionally expressed in endometrial epithelium and is necessary for maintaining the cell function of epithelial cells of endometrium.
Collapse
Affiliation(s)
- Qiuyuan Zhu
- Women's Hospital, School of Medicine, Zhejiang University, China
| | | | | | | | | | | | | |
Collapse
|
14
|
Wu G, Li H, Zhou M, Fang Q, Bao Y, Xu A, Jia W. Mechanism and clinical evidence of lipocalin-2 and adipocyte fatty acid-binding protein linking obesity and atherosclerosis. Diabetes Metab Res Rev 2014; 30:447-56. [PMID: 24214285 DOI: 10.1002/dmrr.2493] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/24/2013] [Accepted: 10/29/2013] [Indexed: 12/19/2022]
Abstract
Obesity is considered to be a chronic inflammatory state in which the dysfunction of adipose tissue plays a central role. The adipokines, which are cytokines secreted by adipose tissue, are key links between obesity and related diseases such as metabolic syndrome and atherosclerosis. LCN2 and A-FABP, both of which are major adipokines predominantly produced in adipose tissue, have recently been shown to be pivotal modulators of vascular function. However, different adipokines modulate the development of atherosclerosis in distinctive manners, which are partly attributable to their unique regulatory mechanisms and functions. This review highlights recent advances in the understanding of the role of two adipokines in mediating chronic inflammation and the pathogenesis of atherosclerosis.
Collapse
Affiliation(s)
- Guangyu Wu
- Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Disease, China; Department of Medicine, Medical School of Soochow University, Suzhou, China
| | | | | | | | | | | | | |
Collapse
|
15
|
Saksi J, Ijäs P, Mäyränpää MI, Nuotio K, Isoviita PM, Tuimala J, Lehtonen-Smeds E, Kaste M, Jula A, Sinisalo J, Nieminen MS, Lokki ML, Perola M, Havulinna AS, Salomaa V, Kettunen J, Jauhiainen M, Kovanen PT, Lindsberg PJ. Low-expression variant of fatty acid-binding protein 4 favors reduced manifestations of atherosclerotic disease and increased plaque stability. ACTA ACUST UNITED AC 2014; 7:588-98. [PMID: 25122052 DOI: 10.1161/circgenetics.113.000499] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Fatty acid-binding protein 4 (FABP4 or aP2 in mice) has been identified as a key regulator of core aspects of cardiometabolic disorders, including lipotoxic endoplasmic reticulum stress in macrophages. A functional promoter polymorphism (rs77878271) of human FABP4 gene has been described resulting in reduced FABP4 transcription. METHODS AND RESULTS We investigated the effects of this low-expression variant of FABP4 on cardiovascular morbidity and carotid atherosclerosis on a population level (n=7491) and in patient cohorts representing endarterectomized patients with advanced carotid atherosclerosis (n=92) and myocardial infarction (n=3432). We found that the low-expression variant was associated with decreased total cholesterol levels (P=0.006) with the largest reduction in variant allele homozygotes. Obese variant allele carriers also showed reduced carotid intima-media thickness (P=0.010) and lower prevalence of carotid plaques (P=0.060). Consistently, the variant allele homozygotes showed 8-fold lower odds for myocardial infarction (P=0.019; odds ratio, 0.12; 95% confidence interval, 0.003-0.801). Within the carotid plaques, the variant allele was associated with a 3.8-fold reduction in FABP4 transcription (P=0.049) and 2.7-fold reduction in apoptosis (activated caspase 3; P=0.043). Furthermore, the variant allele was enriched to patients with asymptomatic carotid stenosis (P=0.038). High FABP4 expression in the carotid plaques was associated with lipid accumulation, intraplaque hemorrhages, plaque ulcerations, and phosphoactivated endoplasmic reticulum stress markers. CONCLUSIONS Our results reveal FABP4 rs77878271 as a novel variant affecting serum total cholesterol levels and cardiovascular risk. A therapeutic regimen reducing FABP4 expression within the atherosclerotic plaque may promote lesion stability through modulation of endoplasmic reticulum stress signaling, and attenuation of apoptosis, lipid burden, and inflammation.
Collapse
Affiliation(s)
- Jani Saksi
- From the Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland (J.S., P.I., K.N., P.M.I., P.J.L.); HUSLAB, Division of Pathology (M.I.M.), Division of Cardiology, Department of Medicine (J.S., M.S.N.), Department of Neurology (P.I., K.N., M.K., P.J.L.), Helsinki University Central Hospital, Helsinki, Finland; Department of Pathology (M.I.M.), Transplantation Laboratory (M.-L.L.), Haartman Institute, Helsinki University, Helsinki, Finland; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland (M.P., J.K.); Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland (P.J.L.); Finnish Red Cross Blood Service, Helsinki, Finland (J.T.); Wihuri Research Institute, Helsinki, Finland (E.L.-S., P.T.K.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (A.J.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (A.J., M.P., A.S.H., V.S., J.K., M.J.); and The Estonian Genome Center, University of Tartu, Tartu, Estonia (M.P.).
| | - Petra Ijäs
- From the Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland (J.S., P.I., K.N., P.M.I., P.J.L.); HUSLAB, Division of Pathology (M.I.M.), Division of Cardiology, Department of Medicine (J.S., M.S.N.), Department of Neurology (P.I., K.N., M.K., P.J.L.), Helsinki University Central Hospital, Helsinki, Finland; Department of Pathology (M.I.M.), Transplantation Laboratory (M.-L.L.), Haartman Institute, Helsinki University, Helsinki, Finland; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland (M.P., J.K.); Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland (P.J.L.); Finnish Red Cross Blood Service, Helsinki, Finland (J.T.); Wihuri Research Institute, Helsinki, Finland (E.L.-S., P.T.K.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (A.J.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (A.J., M.P., A.S.H., V.S., J.K., M.J.); and The Estonian Genome Center, University of Tartu, Tartu, Estonia (M.P.)
| | - Mikko I Mäyränpää
- From the Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland (J.S., P.I., K.N., P.M.I., P.J.L.); HUSLAB, Division of Pathology (M.I.M.), Division of Cardiology, Department of Medicine (J.S., M.S.N.), Department of Neurology (P.I., K.N., M.K., P.J.L.), Helsinki University Central Hospital, Helsinki, Finland; Department of Pathology (M.I.M.), Transplantation Laboratory (M.-L.L.), Haartman Institute, Helsinki University, Helsinki, Finland; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland (M.P., J.K.); Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland (P.J.L.); Finnish Red Cross Blood Service, Helsinki, Finland (J.T.); Wihuri Research Institute, Helsinki, Finland (E.L.-S., P.T.K.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (A.J.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (A.J., M.P., A.S.H., V.S., J.K., M.J.); and The Estonian Genome Center, University of Tartu, Tartu, Estonia (M.P.)
| | - Krista Nuotio
- From the Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland (J.S., P.I., K.N., P.M.I., P.J.L.); HUSLAB, Division of Pathology (M.I.M.), Division of Cardiology, Department of Medicine (J.S., M.S.N.), Department of Neurology (P.I., K.N., M.K., P.J.L.), Helsinki University Central Hospital, Helsinki, Finland; Department of Pathology (M.I.M.), Transplantation Laboratory (M.-L.L.), Haartman Institute, Helsinki University, Helsinki, Finland; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland (M.P., J.K.); Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland (P.J.L.); Finnish Red Cross Blood Service, Helsinki, Finland (J.T.); Wihuri Research Institute, Helsinki, Finland (E.L.-S., P.T.K.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (A.J.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (A.J., M.P., A.S.H., V.S., J.K., M.J.); and The Estonian Genome Center, University of Tartu, Tartu, Estonia (M.P.)
| | - Pia M Isoviita
- From the Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland (J.S., P.I., K.N., P.M.I., P.J.L.); HUSLAB, Division of Pathology (M.I.M.), Division of Cardiology, Department of Medicine (J.S., M.S.N.), Department of Neurology (P.I., K.N., M.K., P.J.L.), Helsinki University Central Hospital, Helsinki, Finland; Department of Pathology (M.I.M.), Transplantation Laboratory (M.-L.L.), Haartman Institute, Helsinki University, Helsinki, Finland; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland (M.P., J.K.); Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland (P.J.L.); Finnish Red Cross Blood Service, Helsinki, Finland (J.T.); Wihuri Research Institute, Helsinki, Finland (E.L.-S., P.T.K.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (A.J.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (A.J., M.P., A.S.H., V.S., J.K., M.J.); and The Estonian Genome Center, University of Tartu, Tartu, Estonia (M.P.)
| | - Jarno Tuimala
- From the Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland (J.S., P.I., K.N., P.M.I., P.J.L.); HUSLAB, Division of Pathology (M.I.M.), Division of Cardiology, Department of Medicine (J.S., M.S.N.), Department of Neurology (P.I., K.N., M.K., P.J.L.), Helsinki University Central Hospital, Helsinki, Finland; Department of Pathology (M.I.M.), Transplantation Laboratory (M.-L.L.), Haartman Institute, Helsinki University, Helsinki, Finland; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland (M.P., J.K.); Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland (P.J.L.); Finnish Red Cross Blood Service, Helsinki, Finland (J.T.); Wihuri Research Institute, Helsinki, Finland (E.L.-S., P.T.K.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (A.J.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (A.J., M.P., A.S.H., V.S., J.K., M.J.); and The Estonian Genome Center, University of Tartu, Tartu, Estonia (M.P.)
| | - Erno Lehtonen-Smeds
- From the Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland (J.S., P.I., K.N., P.M.I., P.J.L.); HUSLAB, Division of Pathology (M.I.M.), Division of Cardiology, Department of Medicine (J.S., M.S.N.), Department of Neurology (P.I., K.N., M.K., P.J.L.), Helsinki University Central Hospital, Helsinki, Finland; Department of Pathology (M.I.M.), Transplantation Laboratory (M.-L.L.), Haartman Institute, Helsinki University, Helsinki, Finland; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland (M.P., J.K.); Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland (P.J.L.); Finnish Red Cross Blood Service, Helsinki, Finland (J.T.); Wihuri Research Institute, Helsinki, Finland (E.L.-S., P.T.K.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (A.J.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (A.J., M.P., A.S.H., V.S., J.K., M.J.); and The Estonian Genome Center, University of Tartu, Tartu, Estonia (M.P.)
| | - Markku Kaste
- From the Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland (J.S., P.I., K.N., P.M.I., P.J.L.); HUSLAB, Division of Pathology (M.I.M.), Division of Cardiology, Department of Medicine (J.S., M.S.N.), Department of Neurology (P.I., K.N., M.K., P.J.L.), Helsinki University Central Hospital, Helsinki, Finland; Department of Pathology (M.I.M.), Transplantation Laboratory (M.-L.L.), Haartman Institute, Helsinki University, Helsinki, Finland; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland (M.P., J.K.); Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland (P.J.L.); Finnish Red Cross Blood Service, Helsinki, Finland (J.T.); Wihuri Research Institute, Helsinki, Finland (E.L.-S., P.T.K.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (A.J.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (A.J., M.P., A.S.H., V.S., J.K., M.J.); and The Estonian Genome Center, University of Tartu, Tartu, Estonia (M.P.)
| | - Antti Jula
- From the Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland (J.S., P.I., K.N., P.M.I., P.J.L.); HUSLAB, Division of Pathology (M.I.M.), Division of Cardiology, Department of Medicine (J.S., M.S.N.), Department of Neurology (P.I., K.N., M.K., P.J.L.), Helsinki University Central Hospital, Helsinki, Finland; Department of Pathology (M.I.M.), Transplantation Laboratory (M.-L.L.), Haartman Institute, Helsinki University, Helsinki, Finland; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland (M.P., J.K.); Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland (P.J.L.); Finnish Red Cross Blood Service, Helsinki, Finland (J.T.); Wihuri Research Institute, Helsinki, Finland (E.L.-S., P.T.K.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (A.J.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (A.J., M.P., A.S.H., V.S., J.K., M.J.); and The Estonian Genome Center, University of Tartu, Tartu, Estonia (M.P.)
| | - Juha Sinisalo
- From the Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland (J.S., P.I., K.N., P.M.I., P.J.L.); HUSLAB, Division of Pathology (M.I.M.), Division of Cardiology, Department of Medicine (J.S., M.S.N.), Department of Neurology (P.I., K.N., M.K., P.J.L.), Helsinki University Central Hospital, Helsinki, Finland; Department of Pathology (M.I.M.), Transplantation Laboratory (M.-L.L.), Haartman Institute, Helsinki University, Helsinki, Finland; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland (M.P., J.K.); Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland (P.J.L.); Finnish Red Cross Blood Service, Helsinki, Finland (J.T.); Wihuri Research Institute, Helsinki, Finland (E.L.-S., P.T.K.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (A.J.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (A.J., M.P., A.S.H., V.S., J.K., M.J.); and The Estonian Genome Center, University of Tartu, Tartu, Estonia (M.P.)
| | - Markku S Nieminen
- From the Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland (J.S., P.I., K.N., P.M.I., P.J.L.); HUSLAB, Division of Pathology (M.I.M.), Division of Cardiology, Department of Medicine (J.S., M.S.N.), Department of Neurology (P.I., K.N., M.K., P.J.L.), Helsinki University Central Hospital, Helsinki, Finland; Department of Pathology (M.I.M.), Transplantation Laboratory (M.-L.L.), Haartman Institute, Helsinki University, Helsinki, Finland; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland (M.P., J.K.); Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland (P.J.L.); Finnish Red Cross Blood Service, Helsinki, Finland (J.T.); Wihuri Research Institute, Helsinki, Finland (E.L.-S., P.T.K.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (A.J.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (A.J., M.P., A.S.H., V.S., J.K., M.J.); and The Estonian Genome Center, University of Tartu, Tartu, Estonia (M.P.)
| | - Marja-Liisa Lokki
- From the Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland (J.S., P.I., K.N., P.M.I., P.J.L.); HUSLAB, Division of Pathology (M.I.M.), Division of Cardiology, Department of Medicine (J.S., M.S.N.), Department of Neurology (P.I., K.N., M.K., P.J.L.), Helsinki University Central Hospital, Helsinki, Finland; Department of Pathology (M.I.M.), Transplantation Laboratory (M.-L.L.), Haartman Institute, Helsinki University, Helsinki, Finland; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland (M.P., J.K.); Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland (P.J.L.); Finnish Red Cross Blood Service, Helsinki, Finland (J.T.); Wihuri Research Institute, Helsinki, Finland (E.L.-S., P.T.K.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (A.J.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (A.J., M.P., A.S.H., V.S., J.K., M.J.); and The Estonian Genome Center, University of Tartu, Tartu, Estonia (M.P.)
| | - Markus Perola
- From the Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland (J.S., P.I., K.N., P.M.I., P.J.L.); HUSLAB, Division of Pathology (M.I.M.), Division of Cardiology, Department of Medicine (J.S., M.S.N.), Department of Neurology (P.I., K.N., M.K., P.J.L.), Helsinki University Central Hospital, Helsinki, Finland; Department of Pathology (M.I.M.), Transplantation Laboratory (M.-L.L.), Haartman Institute, Helsinki University, Helsinki, Finland; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland (M.P., J.K.); Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland (P.J.L.); Finnish Red Cross Blood Service, Helsinki, Finland (J.T.); Wihuri Research Institute, Helsinki, Finland (E.L.-S., P.T.K.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (A.J.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (A.J., M.P., A.S.H., V.S., J.K., M.J.); and The Estonian Genome Center, University of Tartu, Tartu, Estonia (M.P.)
| | - Aki S Havulinna
- From the Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland (J.S., P.I., K.N., P.M.I., P.J.L.); HUSLAB, Division of Pathology (M.I.M.), Division of Cardiology, Department of Medicine (J.S., M.S.N.), Department of Neurology (P.I., K.N., M.K., P.J.L.), Helsinki University Central Hospital, Helsinki, Finland; Department of Pathology (M.I.M.), Transplantation Laboratory (M.-L.L.), Haartman Institute, Helsinki University, Helsinki, Finland; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland (M.P., J.K.); Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland (P.J.L.); Finnish Red Cross Blood Service, Helsinki, Finland (J.T.); Wihuri Research Institute, Helsinki, Finland (E.L.-S., P.T.K.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (A.J.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (A.J., M.P., A.S.H., V.S., J.K., M.J.); and The Estonian Genome Center, University of Tartu, Tartu, Estonia (M.P.)
| | - Veikko Salomaa
- From the Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland (J.S., P.I., K.N., P.M.I., P.J.L.); HUSLAB, Division of Pathology (M.I.M.), Division of Cardiology, Department of Medicine (J.S., M.S.N.), Department of Neurology (P.I., K.N., M.K., P.J.L.), Helsinki University Central Hospital, Helsinki, Finland; Department of Pathology (M.I.M.), Transplantation Laboratory (M.-L.L.), Haartman Institute, Helsinki University, Helsinki, Finland; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland (M.P., J.K.); Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland (P.J.L.); Finnish Red Cross Blood Service, Helsinki, Finland (J.T.); Wihuri Research Institute, Helsinki, Finland (E.L.-S., P.T.K.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (A.J.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (A.J., M.P., A.S.H., V.S., J.K., M.J.); and The Estonian Genome Center, University of Tartu, Tartu, Estonia (M.P.)
| | - Johannes Kettunen
- From the Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland (J.S., P.I., K.N., P.M.I., P.J.L.); HUSLAB, Division of Pathology (M.I.M.), Division of Cardiology, Department of Medicine (J.S., M.S.N.), Department of Neurology (P.I., K.N., M.K., P.J.L.), Helsinki University Central Hospital, Helsinki, Finland; Department of Pathology (M.I.M.), Transplantation Laboratory (M.-L.L.), Haartman Institute, Helsinki University, Helsinki, Finland; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland (M.P., J.K.); Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland (P.J.L.); Finnish Red Cross Blood Service, Helsinki, Finland (J.T.); Wihuri Research Institute, Helsinki, Finland (E.L.-S., P.T.K.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (A.J.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (A.J., M.P., A.S.H., V.S., J.K., M.J.); and The Estonian Genome Center, University of Tartu, Tartu, Estonia (M.P.)
| | - Matti Jauhiainen
- From the Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland (J.S., P.I., K.N., P.M.I., P.J.L.); HUSLAB, Division of Pathology (M.I.M.), Division of Cardiology, Department of Medicine (J.S., M.S.N.), Department of Neurology (P.I., K.N., M.K., P.J.L.), Helsinki University Central Hospital, Helsinki, Finland; Department of Pathology (M.I.M.), Transplantation Laboratory (M.-L.L.), Haartman Institute, Helsinki University, Helsinki, Finland; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland (M.P., J.K.); Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland (P.J.L.); Finnish Red Cross Blood Service, Helsinki, Finland (J.T.); Wihuri Research Institute, Helsinki, Finland (E.L.-S., P.T.K.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (A.J.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (A.J., M.P., A.S.H., V.S., J.K., M.J.); and The Estonian Genome Center, University of Tartu, Tartu, Estonia (M.P.)
| | - Petri T Kovanen
- From the Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland (J.S., P.I., K.N., P.M.I., P.J.L.); HUSLAB, Division of Pathology (M.I.M.), Division of Cardiology, Department of Medicine (J.S., M.S.N.), Department of Neurology (P.I., K.N., M.K., P.J.L.), Helsinki University Central Hospital, Helsinki, Finland; Department of Pathology (M.I.M.), Transplantation Laboratory (M.-L.L.), Haartman Institute, Helsinki University, Helsinki, Finland; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland (M.P., J.K.); Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland (P.J.L.); Finnish Red Cross Blood Service, Helsinki, Finland (J.T.); Wihuri Research Institute, Helsinki, Finland (E.L.-S., P.T.K.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (A.J.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (A.J., M.P., A.S.H., V.S., J.K., M.J.); and The Estonian Genome Center, University of Tartu, Tartu, Estonia (M.P.)
| | - Perttu J Lindsberg
- From the Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland (J.S., P.I., K.N., P.M.I., P.J.L.); HUSLAB, Division of Pathology (M.I.M.), Division of Cardiology, Department of Medicine (J.S., M.S.N.), Department of Neurology (P.I., K.N., M.K., P.J.L.), Helsinki University Central Hospital, Helsinki, Finland; Department of Pathology (M.I.M.), Transplantation Laboratory (M.-L.L.), Haartman Institute, Helsinki University, Helsinki, Finland; Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland (M.P., J.K.); Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland (P.J.L.); Finnish Red Cross Blood Service, Helsinki, Finland (J.T.); Wihuri Research Institute, Helsinki, Finland (E.L.-S., P.T.K.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (A.J.); Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (A.J., M.P., A.S.H., V.S., J.K., M.J.); and The Estonian Genome Center, University of Tartu, Tartu, Estonia (M.P.)
| |
Collapse
|
16
|
Wang Y. Small lipid-binding proteins in regulating endothelial and vascular functions: focusing on adipocyte fatty acid binding protein and lipocalin-2. Br J Pharmacol 2012; 165:603-21. [PMID: 21658023 PMCID: PMC3315034 DOI: 10.1111/j.1476-5381.2011.01528.x] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2011] [Revised: 05/26/2011] [Accepted: 05/31/2011] [Indexed: 12/13/2022] Open
Abstract
UNLABELLED Dysregulated production of adipokines from adipose tissue plays a critical role in the development of obesity-associated cardiovascular abnormalities. A group of adipokines, including adipocyte fatty acid binding protein (A-FABP) and lipocalin-2, possess specific lipid-binding activity and are up-regulated in obese human subjects and animal models. They act as lipid chaperones to promote lipotoxicity in endothelial cells and cause endothelial dysfunction under obese conditions. However, different small lipid-binding proteins modulate the development of vascular complications in distinctive manners, which are partly attributed to their specialized structural features and functionalities. By focusing on A-FABP and lipocalin-2, this review summarizes recent advances demonstrating the causative roles of these newly identified adipose tissue-derived lipid chaperones in obesity-related endothelial dysfunction and cardiovascular complications. The specific lipid-signalling mechanisms mediated by these two proteins are highlighted to support their specialized functions. In summary, A-FABP and lipocalin-2 represent potential therapeutic targets to design drugs for preventing vascular diseases associated with obesity. LINKED ARTICLES This article is part of a themed section on Fat and Vascular Responsiveness. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.165.issue-3.
Collapse
Affiliation(s)
- Yu Wang
- Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong.
| |
Collapse
|
17
|
Fredenburgh LE, Velandia MMS, Ma J, Olszak T, Cernadas M, Englert JA, Chung SW, Liu X, Begay C, Padera RF, Blumberg RS, Walsh SR, Baron RM, Perrella MA. Cyclooxygenase-2 deficiency leads to intestinal barrier dysfunction and increased mortality during polymicrobial sepsis. THE JOURNAL OF IMMUNOLOGY 2011; 187:5255-67. [PMID: 21967897 DOI: 10.4049/jimmunol.1101186] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Sepsis remains the leading cause of death in critically ill patients, despite modern advances in critical care. Intestinal barrier dysfunction may lead to secondary bacterial translocation and the development of the multiple organ dysfunction syndrome during sepsis. Cyclooxygenase (COX)-2 is highly upregulated in the intestine during sepsis, and we hypothesized that it may be critical in the maintenance of intestinal epithelial barrier function during peritonitis-induced polymicrobial sepsis. COX-2(-/-) and COX-2(+/+) BALB/c mice underwent cecal ligation and puncture (CLP) or sham surgery. Mice chimeric for COX-2 were derived by bone marrow transplantation and underwent CLP. C2BBe1 cells, an intestinal epithelial cell line, were treated with the COX-2 inhibitor NS-398, PGD(2), or vehicle and stimulated with cytokines. COX-2(-/-) mice developed exaggerated bacteremia and increased mortality compared with COX-2(+/+) mice following CLP. Mice chimeric for COX-2 exhibited the recipient phenotype, suggesting that epithelial COX-2 expression in the ileum attenuates bacteremia following CLP. Absence of COX-2 significantly increased epithelial permeability of the ileum and reduced expression of the tight junction proteins zonula occludens-1, occludin, and claudin-1 in the ileum following CLP. Furthermore, PGD(2) attenuated cytokine-induced hyperpermeability and zonula occludens-1 downregulation in NS-398-treated C2BBe1 cells. Our findings reveal that absence of COX-2 is associated with enhanced intestinal epithelial permeability and leads to exaggerated bacterial translocation and increased mortality during peritonitis-induced sepsis. Taken together, our results suggest that epithelial expression of COX-2 in the ileum is a critical modulator of tight junction protein expression and intestinal barrier function during sepsis.
Collapse
Affiliation(s)
- Laura E Fredenburgh
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Hong J, Gu W, Zhang Y, Yan Q, Dai M, Shi J, Zhai Y, Wang W, Li X, Ning G. Different association of circulating levels of adipocyte and epidermal fatty acid-binding proteins with metabolic syndrome and coronary atherosclerosis in Chinese adults. Atherosclerosis 2011; 217:194-200. [PMID: 21492859 DOI: 10.1016/j.atherosclerosis.2011.03.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/29/2010] [Revised: 02/21/2011] [Accepted: 03/01/2011] [Indexed: 12/30/2022]
Abstract
AIMS Adipocyte and epidermal fatty acid-binding protein (A-FABP, E-FABP) are cytoplasmic proteins which may play an important role in metabolic diseases. In the present study, we investigated the different association of A-FABP and E-FABP with metabolic syndrome (MetS) and coronary artery disease (CAD) in Chinese adults. METHODS A total of 459 subjects (233 MetS and 226 non-MetS) who had undergone coronary angiography were enrolled in the present study. Serum A-FABP and E-FABP levels, glucose, lipid profiles and other biochemical markers were measured. RESULTS Both serum A-FABP and E-FABP levels were significantly higher in the MetS group than in the non-MetS group (P = 0.040 and 0.045, respectively). Only serum A-FABP levels in the CAD group were significantly higher than in the non-CAD group (12.30 ± 5.45 vs.10.94 ± 4.94 ng/mL, P= 0.008), and significantly increased with the increasing of number of disease vessels (P=0.004). Serum A-FABP levels were also associated with risk of CAD (odds ratio 2.956 [1.295-6.748]; P = 0.010). Adjusting for age, sex, and other conventional risk factors for CAD did not appreciably change the results. No difference was found in serum E-FABP levels between CAD status. Serum E-FABP levels were correlated with fasting and post load 2h plasma glucose, HbA1c, serum total cholesterol and LDL-C concentrations while serum A-FABP levels were correlated with fasting and post load 2h serum insulin concentrations and HOMA-IR (different P<0.05). CONCLUSIONS Our data indicated while both serum A-FABP and E-FABP levels had associations with MetS, only A-FABP was significantly associated with increased risk of CAD in Chinese adults.
Collapse
Affiliation(s)
- Jie Hong
- Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrinology and Metabolism, Endocrine and Metabolic E-Institutes of Shanghai Universities (EISU) and Key Laboratory for Endocrinology and Metabolism of Chinese Health Ministry, Rui-jin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai 200025, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Peeters W, de Kleijn DPV, Vink A, van de Weg S, Schoneveld AH, Sze SK, van der Spek PJ, de Vries JPPM, Moll FL, Pasterkamp G. Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular events. Eur Heart J 2010; 32:1758-68. [PMID: 21059735 DOI: 10.1093/eurheartj/ehq387] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
AIMS There is an increasing need for translational studies identifying molecular targets contributing to atherosclerotic plaque destabilization. Local molecular plaque markers that are related to plaque vulnerability may hold predictive value to identify patients who are at increased risk to suffer from cardiovascular events. Animal studies revealed that adipocyte fatty acid binding protein (FABP4) is associated with the progression of atherosclerosis; however, FABP4 expression studies in human atherosclerotic plaques are lacking. We investigated FABP4 expression in carotid atherosclerotic lesions in relation to plaque composition and future cardiovascular events. METHODS AND RESULTS Atherosclerotic plaques were obtained from 561 patients undergoing carotid endarterectomy (CEA). Plaques were analysed for the presence of macrophages, lipid core, smooth-muscle cells, collagen, calcification, and intraplaque haemorrhage. Patients were followed for 3 years after CEA. The primary outcome was defined as the composite of vascular death, vascular event, and surgical or percutaneous vascular intervention. Fatty acid binding protein levels correlated with unstable plaque characteristics and symptomatic lesions. Patients with increased FABP4 plaque levels showed a two-fold increased risk [HR = 1.99, 95% confidence interval (95% CI) (1.30-3.04)] (P = 0.005) to reach the primary outcome during follow-up. Increased FABP4 levels related to primary outcome, independent from general cardiovascular risk factors [HR = 1.33, 95% CI (1.08-1.65)] (P = 0.008). CONCLUSION FABP4 levels in atherosclerotic lesions are associated with an unstable plaque phenotype and an increased risk for cardiovascular events during follow-up. Besides risk stratification for adverse future cardiovascular events, the outcome of the present study supports the relevance of exploring FABP4 antagonists as a potential pharmaceutical intervention to treat atherosclerotic disease progression.
Collapse
Affiliation(s)
- Wouter Peeters
- Experimental Cardiology Laboratory, Division Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Coleman SL, Park YK, Lee JY. Unsaturated fatty acids repress the expression of adipocyte fatty acid binding protein via the modulation of histone deacetylation in RAW 264.7 macrophages. Eur J Nutr 2010; 50:323-30. [PMID: 21046125 DOI: 10.1007/s00394-010-0140-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2010] [Accepted: 10/18/2010] [Indexed: 01/07/2023]
Abstract
BACKGROUND Adipocyte fatty acid binding protein (A-FABP) present in macrophages has been implicated in the integration of lipid metabolism and inflammatory response, contributing to development of insulin resistance and atherosclerosis. AIM OF THE STUDY This study was conducted to test the hypothesis that the role of fatty acids in the inflammatory pathways is mediated through the modulation of A-FABP expression in macrophages. METHODS Murine RAW 264.7 macrophages were treated with inflammatory insults and fatty acids for quantitative real-time PCR and Western blot analysis. The cells were treated with trichostatin A (TSA), a histone deacetylase inhibitor, for elucidating mechanisms for the regulation of A-FABP expression by fatty acids. RNA interference (RNAi) to knock down A-FABP was utilized to assess its role in inflammatory gene expression. RESULTS When RAW 264.7 were incubated with lipopolysaccharides (LPS; 100 ng/ml) or 2.5 ng/ml of tumor necrosis factor α for 18 h, A-FABP mRNA and protein levels were drastically increased. Unsaturated fatty acids (100 μmol/l in complexed with BSA) such as palmitoleic acid, oleic acid, linoleic acid, linolenic acid, and eicosapentaenoic acid, significantly repressed the basal as well as LPS-induced A-FABP expression, whereas palmitic acid did not elicit the same effect. TSA increased A-FABP mRNA levels and abolished the repressive effect of linoleic acid on A-FABP expression in unstimulated and LPS-stimulated macrophages. Depletion of A-FABP expression by 70-80% using RNAi markedly decreased cyclooxygenase 2 mRNA abundance and potentiated the repression by linoleic acid. CONCLUSION Unsaturated fatty acids inhibited the basal as well as LPS-induced A-FABP expression. The mechanism may involve histone deacetylation and anti-inflammatory effect of unsaturated fatty acids may be at least in part attributed to their repression of A-FABP expression in RAW 264.7 macrophages.
Collapse
Affiliation(s)
- Sara L Coleman
- Department of Nutrition and Health Sciences, University of Nebraska, Lincoln, 68583, USA
| | | | | |
Collapse
|
21
|
Abstract
The intracellular fatty acid-binding proteins (FABPs) are abundantly expressed in almost all tissues. They exhibit high affinity binding of a single long-chain fatty acid, with the exception of liver FABP, which binds two fatty acids or other hydrophobic molecules. FABPs have highly similar tertiary structures consisting of a 10-stranded antiparallel β-barrel and an N-terminal helix-turn-helix motif. Research emerging in the last decade has suggested that FABPs have tissue-specific functions that reflect tissue-specific aspects of lipid and fatty acid metabolism. Proposed roles for FABPs include assimilation of dietary lipids in the intestine, targeting of liver lipids to catabolic and anabolic pathways, regulation of lipid storage and lipid-mediated gene expression in adipose tissue and macrophages, fatty acid targeting to β-oxidation pathways in muscle, and maintenance of phospholipid membranes in neural tissues. The regulation of these diverse processes is accompanied by the expression of different and sometimes multiple FABPs in these tissues and may be driven by protein-protein and protein-membrane interactions.
Collapse
Affiliation(s)
- Judith Storch
- From the Department of Nutritional Sciences and the Rutgers Center for Lipid Research, Rutgers University, New Brunswick, New Jersey 08901.
| | - Alfred E Thumser
- Division of Biochemical Sciences, University of Surrey, Guildford, Surrey GU2 7XH, United Kingdom.
| |
Collapse
|
22
|
Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus. Am J Cardiol 2010; 106:1118-23. [PMID: 20920650 DOI: 10.1016/j.amjcard.2010.06.028] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/29/2009] [Revised: 06/03/2010] [Accepted: 06/03/2010] [Indexed: 01/22/2023]
Abstract
Fatty acid-binding proteins (FABPs) 4 and 5 play coordinated roles in rodent models of inflammation, insulin resistance, and atherosclerosis, but little is known of their role in human disease. The aim of this study was to examine the hypothesis that plasma adipocyte and macrophage FABP4 and FABP5 levels would provide additive value in the association with metabolic and inflammatory risk factors for cardiovascular disease as well as subclinical atherosclerosis. Using the Penn Diabetes Heart Study (PDHS; n = 806), cross-sectional analysis of FABP4 and FABP5 levels with metabolic and inflammatory parameters and with coronary artery calcium, a measure of subclinical coronary atherosclerosis, was performed. FABP4 and FABP5 levels had strong independent associations with the metabolic syndrome (for a 1-SD change in FABP levels, odds ratio [OR] 1.85, 95% confidence interval [CI] 1.43 to 2.23, and OR 1.66, 95% CI 1.41 to 1.95, respectively) but had differential associations with metabolic syndrome components. FABP4 and FABP5 were also independently associated with C-reactive protein and interleukin-6 levels. FABP4 (OR 1.26, 95% CI 1.05 to 1.52) but not FABP5 (OR 1.13, 95% CI 0.97 to 1.32) was associated with the presence of coronary artery calcium. An integrated score combining FABP4 and FABP5 quartile data had even stronger associations with the metabolic syndrome, C-reactive protein, interleukin-6, and coronary artery calcium compared to either FABP alone. In conclusion, this study provides evidence for an additive relation of FABP4 and FABP5 with the metabolic syndrome, inflammatory cardiovascular disease risk factors, and coronary atherosclerosis in type 2 diabetes mellitus. These findings suggest that FABP4 and FABP5 may represent mediators of and biomarkers for metabolic and cardiovascular disease in type 2 diabetes mellitus.
Collapse
|
23
|
Affiliation(s)
- Partha Chakrabarti
- Boston University School of Medicine, Department of Biochemistry, K110, 715 Albany Street, Boston, Massachusetts 02118, USA.
| |
Collapse
|
24
|
Bot M, Bot I, Lopez-Vales R, van de Lest CHA, Saulnier-Blache JS, Helms JB, David S, van Berkel TJC, Biessen EAL. Atherosclerotic lesion progression changes lysophosphatidic acid homeostasis to favor its accumulation. THE AMERICAN JOURNAL OF PATHOLOGY 2010; 176:3073-84. [PMID: 20431029 DOI: 10.2353/ajpath.2010.090009] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Lysophosphatidic acid (LPA) accumulates in the central atheroma of human atherosclerotic plaques and is the primary platelet-activating lipid constituent of plaques. Here, we investigated the enzymatic regulation of LPA homeostasis in atherosclerotic lesions at various stages of disease progression. Atherosclerotic lesions were induced in carotid arteries of low-density lipoprotein receptor-deficient mice by semiconstrictive collar placement. At 2-week intervals after collar placement, lipids and RNA were extracted from the vessel segments carrying the plaque. Enzymatic-and liquid chromatography-mass spectrometry-based lipid profiling revealed progressive accumulation of LPA species in atherosclerotic tissue preceded by an increase in lysophosphatidylcholine, a precursor in LPA synthesis. Plaque expression of LPA-generating enzymes cytoplasmic phospholipase A(2)IVA (cPLA(2)IVA) and calcium-independent PLA(2)VIA (iPLA(2)VIA) was gradually increased, whereas that of the LPA-hydrolyzing enzyme LPA acyltransferase alpha was quenched. Increased expression of cPLA(2)IVA and iPLA(2)VIA in advanced lesions was confirmed by immunohistochemistry. Moreover, LPA receptors 1 and 2 were 50% decreased and sevenfold upregulated, respectively. Therefore, key proteins in LPA homeostasis are increasingly dysregulated in the plaque during atherogenesis, favoring intracellular LPA production. This might at least partly explain the observed progressive accumulation of this thrombogenic proinflammatory lipid in human and mouse plaques. Thus, intervention in the enzymatic LPA production may be an attractive measure to lower intraplaque LPA content, thereby reducing plaque progression and thrombogenicity.
Collapse
Affiliation(s)
- Martine Bot
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Gorlaeus Laboratories, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands.
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Song J, Ren P, Zhang L, Wang XL, Chen L, Shen YH. Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4. Biochem Biophys Res Commun 2010; 393:89-94. [PMID: 20102700 DOI: 10.1016/j.bbrc.2010.01.086] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2010] [Accepted: 01/17/2010] [Indexed: 10/19/2022]
Abstract
OBJECTIVE The accumulation of lipids in macrophages contributes to the development of atherosclerosis. Strategies to reduce lipid accumulation in macrophages may have therapeutic potential for preventing and treating atherosclerosis and cardiovascular complications. The antidiabetic drug metformin has been reported to reduce lipid accumulation in adipocytes. In this study, we examined the effects of metformin on lipid accumulation in macrophages and investigated the mechanisms involved. METHODS AND RESULTS We observed that metformin significantly reduced palmitic acid (PA)-induced intracellular lipid accumulation in macrophages. Metformin promoted the expression of carnitine palmitoyltransferase I (CPT-1), while reduced the expression of fatty acid-binding protein 4 (FABP4) which was involved in PA-induced lipid accumulation. Quantitative real-time PCR showed that metformin regulates FABP4 expression at the transcriptional level. We identified forkhead transcription factor FOXO1 as a positive regulator of FABP4 expression. Inhibiting FOXO1 expression with FOXO1 siRNA significantly reduced basal and PA-induced FABP4 expression. Overexpression of wild-type FOXO1 and constitutively active FOXO1 significantly increased FABP4 expression, whereas dominant negative FOXO1 dramatically decreased FABP4 expression. Metformin reduced FABP4 expression by promoting FOXO1 nuclear exclusion and subsequently inhibiting its activity. CONCLUSIONS Taken together, these results suggest that metformin reduces lipid accumulation in macrophages by repressing FOXO1-mediated FABP4 transcription. Thus, metformin may have a protective effect against lipid accumulation in macrophages and may serve as a therapeutic agent for preventing and treating atherosclerosis in metabolic syndrome.
Collapse
Affiliation(s)
- Jun Song
- Qilu Hospital, Shandong University, Jinan, Shandong, China
| | | | | | | | | | | |
Collapse
|
26
|
Szameit S, Vierlinger K, Farmer L, Tuschl H, Noehammer C. Gene expression studies in cultured dendritic cells: new indicators for the discrimination of skin sensitizers and irritantsin vitro. Clin Exp Allergy 2009; 39:856-68. [DOI: 10.1111/j.1365-2222.2009.03222.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Storch J, Corsico B. The emerging functions and mechanisms of mammalian fatty acid-binding proteins. Annu Rev Nutr 2008; 28:73-95. [PMID: 18435590 DOI: 10.1146/annurev.nutr.27.061406.093710] [Citation(s) in RCA: 312] [Impact Index Per Article: 19.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Fatty acid-binding proteins (FABPs) are abundant intracellular proteins that bind long-chain fatty acids with high affinity. Nine separate mammalian FABPs have been identified, and their tertiary structures are highly conserved. The FABPs have unique tissue-specific distributions that have long suggested functional differences among them. In the last decade, considerable progress has been made in understanding the specific functions of the FABPs and, in some cases, their mechanisms of action at the molecular level. The FABPs appear to be involved in the extranuclear compartments of the cell by trafficking their ligands within the cytosol via interactions with organelle membranes and specific proteins. Several members of the FABP family have been shown to function directly in the regulation of cognate nuclear transcription factor activity via ligand-dependent translocation to the nucleus. This review will focus on these emerging functions and mechanisms of the FABPs, highlighting the unique functional properties of each as well as the similarities among them.
Collapse
Affiliation(s)
- Judith Storch
- Department of Nutritional Sciences and the Rutgers Center for Lipid Research, School of Environmental and Biological Sciences, Rutgers University, New Brunswick, New Jersey 08901, USA.
| | | |
Collapse
|
28
|
Aeberli I, Beljean N, Lehmann R, I'Allemand D, Spinas GA, Zimmermann MB. The increase of fatty acid-binding protein aP2 in overweight and obese children: interactions with dietary fat and impact on measures of subclinical inflammation. Int J Obes (Lond) 2008; 32:1513-20. [PMID: 18679408 DOI: 10.1038/ijo.2008.128] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
BACKGROUND In adults, circulating aP2 may link obesity, inflammation and the metabolic syndrome, but there are few data in children. Experimental models support that dietary factors, particularly dietary fat, may be major determinants of phenotype. OBJECTIVE The aim of this study was to investigate, in normal, overweight and obese children, the relationships among aP2, the metabolic syndrome, inflammation and diet. DESIGN This was a cross-sectional study conducted in Northern Switzerland. SUBJECTS Subjects for this study were 6- to 14-year-old, prepubertal and early pubertal, normal weight, overweight and obese children (n=124). MAIN OUTCOME MEASURES Body mass index (BMI), body fat percent, waist-to-hip ratio, blood pressure, circulating aP2, fasting insulin, C-reactive protein (CRP), plasma lipids and dietary intakes of macro- and micronutrients were determined. RESULTS Circulating aP2 markedly increased with increasing central and total adiposity, and predicted measures of insulin resistance. Independent of BMI standard deviation scores and puberty, aP2 correlated with intake of the antioxidant vitamins A, C and E as well as circulating concentrations of CRP, leptin and low-density lipoprotein cholesterol. Children with lower aP2 concentrations consuming high-fat diets did not show an increase in fasting insulin or CRP, whereas those with higher aP2 concentrations showed marked increases in these measures with high intakes of fat or saturated fat. CONCLUSIONS Increased central and overall adiposity in children are associated with higher circulating aP2 concentrations. In children with high dietary intakes of total fat and saturated fat, but not those with low intakes, higher aP2 concentrations are associated with measures of insulin resistance and inflammation.
Collapse
Affiliation(s)
- I Aeberli
- Human Nutrition Laboratory, Institute of Food Science and Nutrition, Zürich, Switzerland.
| | | | | | | | | | | |
Collapse
|
29
|
Tso AWK, Xu A, Chow WS, Lam KSL. Adipose tissue and the metabolic syndrome: focusing on adiponectin and several novel adipokines. Biomark Med 2008; 2:239-52. [DOI: 10.2217/17520363.2.3.239] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
The metabolic syndrome represents a cluster of metabolic risk factors that predispose an individual to an increased risk for Type 2 diabetes, cardiovascular diseases and their associated morbidity and mortality. Visceral obesity is thought to be a major culprit. Adipokines secreted from the adipose tissue are now believed to be key factors mediating the metabolic and inflammatory effects of obesity. In this review, we shall examine the evidence suggesting that several novel adipokines, adiponectin, adipocyte fatty acid-binding protein, retinol-binding protein-4 and lipocalin-2, may hold promise as important clinical biomarkers to identify individuals at risk for the metabolic syndrome and related comorbidities.
Collapse
Affiliation(s)
- Annette WK Tso
- Department of Medicine, Queen Mary Hospital, University of Hong Kong, 102 Pokfulam Road, Hong Kong
| | - Aimin Xu
- Department of Medicine, Queen Mary Hospital, University of Hong Kong, 102 Pokfulam Road, Hong Kong
| | - Wing Sun Chow
- Department of Medicine, Queen Mary Hospital, University of Hong Kong, 102 Pokfulam Road, Hong Kong
| | - Karen SL Lam
- Department of Medicine, Queen Mary Hospital, University of Hong Kong, 102 Pokfulam Road, Hong Kong
- Research Centre of Heart, Brain, Hormone and Healthy Aging, University of Hong Kong, Hong Kong
| |
Collapse
|
30
|
Hoo RL, Yeung DC, Lam KS, Xu A. Inflammatory biomarkers associated with obesity and insulin resistance: a focus on lipocalin-2 and adipocyte fatty acid-binding protein. Expert Rev Endocrinol Metab 2008; 3:29-41. [PMID: 30743783 DOI: 10.1586/17446651.3.1.29] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Obesity is an important risk factor for a cluster of metabolic and cardiovascular diseases, including insulin resistance, Type 2 diabetes, nonalcoholic fatty liver disease and atherosclerosis. Systemic low-grade inflammation, characterized by elevated circulating concentrations of proinflammatory factors, has recently been proposed to be a key mediator that links obesity with its medical complications. Adipose tissue is now recognized as the major contributor to systemic inflammation associated with obesity. As obesity develops, adipose tissue is infiltrated with activated macrophages. The 'inflamed' adipose tissue secretes a large number of proinflammatory adipokines and/or cytokines, which can act either in an autocrine manner to perpetuate local inflammation or in an endocrine manner to induce insulin resistance and endothelial dysfunction. In this review, we summarize recent advances in several newly identified adipose tissue-derived inflammatory factors, with the focus on lipocalin-2 and adipocyte fatty acid-binding protein (A-FABP). Both lipocalin-2 and A-FABP possess lipid-binding properties and are important integrators of metabolic and inflammatory pathways. A growing body of evidence from experimental, epidemiological and genetic studies suggests that both lipocalin-2 and A-FABP represent a novel class of serum biomarkers for risk prediction and therapeutic intervention of obesity-related medical complications.
Collapse
Affiliation(s)
- Ruby Lc Hoo
- a University of Hong Kong, Department of Medicine and Research Centre of Heart, Brain, Hormone and Healthy Aging, Li Ka Shing Faculty of Medicine, L8-40, 21 Sassoon Road, Hong Kong, China.
| | - Dennis Cy Yeung
- b University of Hong Kong, Department of Medicine and Research Centre of Heart, Brain, Hormone and Healthy Aging, Li Ka Shing Faculty of Medicine, L8-40, 21 Sassoon Road, Hong Kong, China.
| | - Karen Sl Lam
- c University of Hong Kong, Department of Medicine and Research Centre of Heart, Brain, Hormone and Healthy Aging, Li Ka Shing Faculty of Medicine, L8-40, 21 Sassoon Road, Hong Kong, China.
| | - Aimin Xu
- d University of Hong Kong, Department of Medicine and Research Centre of Heart, Brain, Hormone and Healthy Aging, Li Ka Shing Faculty of Medicine, L8-40, 21 Sassoon Road, Hong Kong, China.
| |
Collapse
|
31
|
Abstract
Inflammation underpins the development of atherosclerosis. Initiation and progression of vascular inflammation involves a complex cellular network, with macrophages as major contributors. Activated macrophages produce proinflammatory mediators, bridge innate and adaptive immunity, regulate lipid retention, and participate directly in vascular repair and remodeling. Recent efforts to elucidate molecular mechanisms involved in the regulation of vascular inflammation in atherosclerosis have implicated several families of innate immune recognition receptors in inflammatory activation during the course of this disease. This article reviews our current understanding of innate immune recognition receptors, signaling pathways, and putative ligands implicated in activation of macrophages in the disease. In its final section, we propose a model for the role of macrophages in bridging inflammation and atherosclerosis from the perspective of innate immune recognition and activation.
Collapse
Affiliation(s)
- Zhong-qun Yan
- Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden.
| | | |
Collapse
|
32
|
The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis 2007; 199:147-53. [PMID: 17983623 DOI: 10.1016/j.atherosclerosis.2007.09.032] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/23/2007] [Revised: 09/18/2007] [Accepted: 09/24/2007] [Indexed: 01/22/2023]
Abstract
BACKGROUND The incidence of metabolic abnormalities in HIV-infected patients is increasing. Fatty acid binding protein-4 (FABP4) is an emerging biomarker for metabolic-related disturbances. We aimed to study FABP4 as a marker of metabolic syndrome (MS) or lipodystrophy (LD) in HIV patients. METHODS FABP4 plasma concentrations were measured by enzyme-linked immunoassays in 183 HIV-infected patients, enrolled as part of a study aimed at identifying predictors of atherosclerosis. The presence of MS or LD was diagnosed according to standard clinical methods. Univariate and multivariate statistical analyses were performed. RESULTS FABP4 concentration was significantly higher in those patients with either MS or LD criteria than those without any metabolic disturbance. Similarly, FABP4 concentration significantly increased with an increasing of MS features and was strongly correlated with body-mass index, triglycerides, HDL-cholesterol concentrations, insulin and blood pressure. Patients in the highest quartile of FABP4 presented a six-fold increased odds ratio for MS and a three-fold increased odds for LD, adjusted by age, sex, body-mass index and the antiretroviral therapy. CONCLUSIONS FABP4 is a strong plasma marker of metabolic disturbances in HIV-infected patients, and therefore, could serve to guide therapeutic intervention in this group of patients.
Collapse
|
33
|
Sulsky R, Magnin DR, Huang Y, Simpkins L, Taunk P, Patel M, Zhu Y, Stouch TR, Bassolino-Klimas D, Parker R, Harrity T, Stoffel R, Taylor DS, Lavoie TB, Kish K, Jacobson BL, Sheriff S, Adam LP, Ewing WR, Robl JA. Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). Bioorg Med Chem Lett 2006; 17:3511-5. [PMID: 17502136 DOI: 10.1016/j.bmcl.2006.12.044] [Citation(s) in RCA: 117] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2006] [Revised: 12/12/2006] [Accepted: 12/13/2006] [Indexed: 01/10/2023]
Abstract
Herein we report the first disclosure of biphenyl azoles that are nanomolar binders of adipocyte fatty acid binding protein (aFABP or aP2) with up to thousand-fold selectivity against muscle fatty acid binding protein and epidermal fatty acid binding protein. In addition a new radio-ligand to determine binding against the three fatty acid binding proteins was also synthesized.
Collapse
Affiliation(s)
- Richard Sulsky
- Department of Metabolic Disease Chemistry, Bristol Myers-Squibb Pharmaceutical Research Institute, PO Box 5400, Princeton, NJ 08543-5400, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Virok D, Kis Z, Kari L, Barzo P, Sipka R, Burian K, Nelson DE, Jackel M, Kerenyi T, Bodosi M, Gönczol E, Endresz V. Chlamydophila pneumoniae and human cytomegalovirus in atherosclerotic carotid plaques--combined presence and possible interactions. Acta Microbiol Immunol Hung 2006; 53:35-50. [PMID: 16696549 DOI: 10.1556/amicr.53.2006.1.3] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
The aim of our study was to investigate the combination of Chlamydophila pneumoniae and human cytomegalovirus (HCMV) as a pathogenic factor in atherosclerosis. Accordingly, we tested by means of PCR and immunohistochemistry the presence of these pathogens in the same atherosclerotic carotid specimen. The histology of the samples and the patients' antibodies against these pathogens were evaluated. Further, we examined the impact of C. pneumoniae and HCMV infection on the gene expression of the human monocytic cell line U937. Six of the 22 samples contained only C. pneumoniae, 4 contained only HCMV, 7 contained both C. pneumoniae DNA and/or antigens of both pathogens, and 5 samples were negative. No correlation was found between the presence of these microbes and either the cellular structure of the plaques, or the serostatus of the patients. The infection of U937 cells with HCMV and especially C. pneumoniae induced inflammation and atherosclerosis-related genes. Furthermore, the doubly-infected cells produced higher levels of the mRNA of pro-platelet basic protein and fatty acid binding protein 4. In conclusion, C. pneumoniae is often present in combination with HCMV in atherosclerotic carotid lesions. The in vitro coinfection model reveals that the doubly-infected monocytes are potent expressors of proatherosclerotic genes, suggesting that this coinfected population may accelerate the process of atherosclerosis.
Collapse
Affiliation(s)
- D Virok
- Department of Medical Microbiology and Immunobiology, University of Szeged, Dóm tér 10, H-6720 Szeged, Hungary
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Fu Y, Luo L, Luo N, Garvey WT. Lipid metabolism mediated by adipocyte lipid binding protein (ALBP/aP2) gene expression in human THP-1 macrophages. Atherosclerosis 2005; 188:102-11. [PMID: 16313911 DOI: 10.1016/j.atherosclerosis.2005.10.041] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/06/2005] [Revised: 09/29/2005] [Accepted: 10/22/2005] [Indexed: 10/25/2022]
Abstract
The critical initiating event in atherogenesis involves the invasion of monocytes through the endothelial wall of arteries, and their transformation from macrophages into foam cells. Human THP-1 monocytic cells can be induced to differentiate into macrophages by phorbol myristate acetate (PMA) treatment, and can then be converted into foam cells by exposure to oxidized low-density lipoprotein (oxLDL). We previously reported that adipocyte lipid binding protein (ALBP/aP2) is a gene that is highly up-regulated in foam cells in response to oxLDL. Here, we showed that overexpression of the ALBP gene using a lentiviral construct in macrophage foam cells enhanced the accumulations of cholesterol and triglyceride, probably due to an increased expression of the scavenger receptor type AI (SR-AI), which plays an important role in cell lipid metabolism. Moreover, we determined that the expression of acyl-coenzyme A: cholesterol-acyltransferase 1 (ACAT1) gene was up-regulated by the overexpression of ALBP gene, and on the other hand, the ATP-binding cassette A1 (ABCA1) gene and hormone sensitive lipase (HSL) gene, which mediate separately cholesterol efflux and cholesterol ester hydrolysis in the macrophage cells, were down-regulated by the overexpression of ALBP gene in these cells. Finally, our data indicated that oxLDL regulates expression of ALBP related to two peroxisome proliferator-responsive elements (PPREs) which are located in ALBP promoter region. These results have determined that ALBP gene expression accelerates cholesterol and triglyceride accumulation in macrophage foam cells and affects some key gene expression for lipid metabolism, suggesting some pivotal roles of ALBP in lipid metabolism for macrophage foam cell formation.
Collapse
Affiliation(s)
- Yuchang Fu
- Department of Nutrition Sciences, University of Alabama at Birmingham, 1675 University Boulevard, Birmingham, AL 35294-3360, USA.
| | | | | | | |
Collapse
|
36
|
Conway JP, Kinter M. Proteomic and transcriptomic analyses of macrophages with an increased resistance to oxidized low density lipoprotein (oxLDL)-induced cytotoxicity generated by chronic exposure to oxLDL. Mol Cell Proteomics 2005; 4:1522-40. [PMID: 16006650 DOI: 10.1074/mcp.m500111-mcp200] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The uptake of oxidized low density lipoprotein (oxLDL) by macrophages leads to foam cell formation and fatty streaks, which represent early sites of potential atheroma development. We developed a cell culture model of chronic oxLDL exposure to determine whether hallmark parameters of oxLDL uptake and cytotoxicity are altered during foam cell formation and to determine changes in protein and mRNA expression that distinguish acute and chronic oxLDL exposure. Although the extent of oxLDL uptake did not change, a resistance to oxLDL-induced cytotoxicity was observed in the chronically exposed cells. Macrophages that have been chronically exposed to oxLDL required a 40% higher concentration of oxLDL to achieve 50% survival in a 48-h treatment relative to macrophages subjected to a single oxLDL exposure. A main feature of the differentially expressed proteome was a series of significantly overexpressed antioxidant and antioxidant-related proteins in the oxLDL-exposed cells. A large proportion of these proteins (45%) was overexpressed in the chronically exposed cells prior to the oxLDL treatment, indicative of the unique phenotype produced by the chronic treatment. Analysis of the transcriptome also revealed a broad increase in the expression of antioxidant and antioxidant-related proteins. In addition, the transcriptome experiments found an increased inflammatory response under conditions of both acute and chronic oxLDL exposure. Overall the combined functional, proteomic, and transcriptomic experiments show that macrophages respond to oxLDL by developing an oxidative stress resistance that increases and stabilizes with chronic exposure. Furthermore this protective response and the increased foam cell survival that it supports amplifies their proatherogenic role by promoting a continued inflammatory state.
Collapse
Affiliation(s)
- James P Conway
- Department of Cell Biology, Lerner Research Institute, Cleveland Clinic Foundation, and the Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio 44106, USA
| | | |
Collapse
|
37
|
Bouloumié A, Curat CA, Sengenès C, Lolmède K, Miranville A, Busse R. Role of macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care 2005; 8:347-54. [PMID: 15930956 DOI: 10.1097/01.mco.0000172571.41149.52] [Citation(s) in RCA: 182] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
PURPOSE OF REVIEW White adipose tissue is necessary for optimal energy homeostasis and the excessive development of fat mass is clearly associated with the metabolic syndrome. The fact that adipocytes secrete a number of specific factors or 'adipokines' has forced a reassessment of the involvement of adipose tissue in a wide range of physiological and pathophysiological processes. Obesity has recently been described as a 'low-grade' inflammatory condition, a state proposed to represent a common determinator in the genesis of obesity-associated pathologies, i.e. diabetes and atherosclerosis. RECENT FINDINGS Recent reports of an increase in the number of macrophages that infiltrate the fat mass in obese individuals led to the suggestion that adipose tissue itself is a source and site of inflammation. SUMMARY This review summarizes recent data on the characterization of the macrophage population in fat tissue. Their origin, fate and activation will be considered. The potential involvement of adipose tissue macrophages in the development of insulin resistance and vascular pathologies, as well as in the control of adipose tissue growth and metabolism, will be examined.
Collapse
Affiliation(s)
- Anne Bouloumié
- Institute of Cardiovascular Physiology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany.
| | | | | | | | | | | |
Collapse
|
38
|
Fortier M, Soni K, Laurin N, Wang SP, Mauriège P, Jirik FR, Mitchell GA. Human hormone-sensitive lipase (HSL): expression in white fat corrects the white adipose phenotype of HSL-deficient mice. J Lipid Res 2005; 46:1860-7. [PMID: 15961788 DOI: 10.1194/jlr.m500081-jlr200] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
In white adipose tissue (WAT), hormone-sensitive lipase (HSL) can mediate lipolysis, a central pathway in obesity and diabetes. Gene-targeted HSL-deficient (HSL-/-) mice with no detectable HSL peptide or activity (measured as cholesteryl esterase) have WAT abnormalities, including low mass, marked heterogeneity of cell diameter, increased diacylglycerol content, and low beta-adrenergic stimulation of adipocyte lipolysis. Three transgenic mouse strains preferentially expressing human HSL in WAT were bred to a HSL-/- background. One, HSL-/- N, expresses normal human HSL (41.3 +/- 9.1% of normal activity); two express a serine-to-alanine mutant (S554A) initially hypothesized to be constitutively active: HSL-/- ML, 50.3 +/- 12.3% of normal, and HSL-/- MH, 69.8 +/- 15.8% of normal. In WAT, HSL-/- N mice resembled HSL+/+ controls in WAT mass, histology, diacylglyceride content, and lipolytic response to beta-adrenergic agents. In contrast, HSL-/- ML and HSL-/- MH mice resembled nontransgenic HSL-/- mice, except that diacylglycerol content and perirenal and inguinal WAT masses approached normal in HSL-/- MH mice. Therefore, 1) WAT expression of normal human HSL markedly improves HSL-/- WAT biochemically, physiologically, and morphologically; 2) similar levels of S554A HSL have a low physiological effect despite being active in vitro; and 3) diacylglycerol accumulation is not essential for the development of the characteristic WAT pathology of HSL-/- mice.
Collapse
Affiliation(s)
- Mélanie Fortier
- Division of Medical Genetics, Research Centre, Sainte-Justine Hospital, Montréal, Québec, Canada
| | | | | | | | | | | | | |
Collapse
|
39
|
Kazemi MR, McDonald CM, Shigenaga JK, Grunfeld C, Feingold KR. Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arterioscler Thromb Vasc Biol 2005; 25:1220-4. [PMID: 15705927 DOI: 10.1161/01.atv.0000159163.52632.1b] [Citation(s) in RCA: 122] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Toll-like receptors (TLRs) recognize pathogens and mediate signaling pathways important for host defense. Recent studies implicate TLR polymorphisms in atherosclerosis risk in humans. Adipocyte fatty acid-binding protein (aP2) is present in macrophages and has an important role in atherosclerotic plaque development. We investigated aP2 expression in RAW 264.7 cells treated with lipopolysaccharide (LPS) and other TLR agonists and assessed lipid accumulation in these activated murine macrophages. METHODS AND RESULTS Stimulation with LPS, a TLR4 ligand, resulted in a 56-fold increase in aP2 mRNA expression, and zymosan, a TLR2 ligand, induced an approximately 1500-fold increase. Polyinosine: polycytidylic acid (poly I:C), a TLR3 ligand, led to a 9-fold increase. Levels of aP2 protein were significantly increased in LPS or zymosan-treated macrophages compared with control or poly I:C-treated cells. In addition, the cholesteryl ester content of LPS or zymosan-treated macrophages was approximately 5-fold greater in the presence of low-density lipoprotein, and triglyceride content was approximately 2-fold greater in the absence of exogenous lipid than control or poly I:C-treated cells. CONCLUSIONS Expression of macrophage aP2 is induced on TLR activation and parallels increases in cholesteryl ester and triglyceride levels. These results provide a molecular link between the known roles of TLR and aP2 in foam cell formation.
Collapse
Affiliation(s)
- Mahmood R Kazemi
- Metabolism Section, Department of Veterans Affairs Medical Center, San Francisco, Calif, CA 94121, USA.
| | | | | | | | | |
Collapse
|
40
|
Doi H, Masaki N, Takahashi H, Komatsu H, Fujimori K, Satomi S. A New Preadipocyte Cell Line, AP-18, Established from Adult Mouse Adipose Tissue. TOHOKU J EXP MED 2005; 207:209-16. [PMID: 16210832 DOI: 10.1620/tjem.207.209] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Establishing preadipocyte cell lines from mature adipose tissues could help lead to a better understanding of adipogenesis. We have established a unique preadipocyte cell line, AP-18, derived from the subepidermal layer of ear skin from an adult C3H/HeM mouse. AP-18 cells exhibit fibroblast-like morphology, slow growth, and contact inhibition. The doubling time of AP-18 cells is 50-60 h, which is about 2-fold longer than that of well-known 3T3-L1 cells derived from mouse embryos. A small population of AP-18 cells spontaneously differentiates into adipocytes by 8 days after confluence, as judged by the accumulation of triglyceride droplets. Treatment of confluent AP-18 preadipocytes with adipogenic agents, containing dexamethasone, 3-methyl-1-isobutylxanthine, and insulin, increased triglyceride contents about 5-fold compared to the contents in untreated cells. We also analyzed mRNA expression profiles for key transcription factors involved in adipocyte differentiation, peroxisome proliferator-activated receptor (PPAR)gamma and the CCAAT/enhancer binding protein (C/EBP) family, and for differentiation markers, aP2, adipocyte-specific fatty acid-binding protein and adipsin, adipocyte-specific serine protease. AP-18 preadipocytes express mRNAs for C/EBPbeta, C/EBPalpha, PPARgamma, and aP2 before differentiation, but not adipsin mRNA. Expression of aP2 mRNA was increased in fully differentiated AP-18 cells. Likewise, expression of adipsin mRNA was increased after induced differentiation of AP-18 cells and reached the highest level in fully differentiated adipocytes. Thus, differentiation of AP-18 cells is associated with the increased expression of aP2 and adipsin mRNAs. The newly established AP-18 cell line provides a useful model for investigating adipocyte differentiation and adipogenesis.
Collapse
Affiliation(s)
- Hideyuki Doi
- Division of Advanced Surgical Science and Technology, Graduate School of Medicine Tohoku University, Sendai.
| | | | | | | | | | | |
Collapse
|
41
|
Schachtrup C, Scholzen TE, Grau V, Luger TA, Sorg C, Spener F, Kerkhoff C. L-FABP is exclusively expressed in alveolar macrophages within the myeloid lineage. Int J Biochem Cell Biol 2004; 36:2042-53. [PMID: 15203117 DOI: 10.1016/j.biocel.2004.03.008] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2003] [Revised: 03/15/2004] [Accepted: 03/19/2004] [Indexed: 01/15/2023]
Abstract
Peroxisome proliferator-activated receptors (PPARs) play a role in inflammation and, in particular, PPARgamma is involved in monocyte/macrophage differentiation. Members of the fatty acid-binding protein (FABP) family have been reported to function as transactivators for PPARs. Therefore, the expression of PPARs and FABPs in the myeloid lineage was investigated by real-time PCR and immunofluorescence analysis. We found adipocyte-, epidermal-, and heart-type FABP to be ubiquitously expressed within the myeloid lineage. In contrast, liver-type FABP was exclusively detected in murine alveolar macrophages (AM), confirmed on protein level by double fluorescence analysis. The PPAR subtypes also showed a temporally and spatially regulated expression pattern in myeloid cells: the beta-subtype was expressed in bone marrow, peritoneal, and alveolar macrophages, whereas it was not detected in dendritic cells (DCs). The gamma1-isoform was present in all cells, however, at different levels, whereas the gamma2-isoform was expressed in alveolar macrophages and dendritic cells. A low level PPARalpha mRNA could be detected in peritoneal macrophages and immature dendritic cells but not in mature dendritic cells and bone marrow macrophages. Interestingly, PPARalpha mRNA was also absent in the alveolar macrophages although liver-type FABP was expressed, indicating that gene expression of liver-type FABP was independent of PPARalpha. Since liver-type FABP is known as transactivator of PPARgamma the simultaneous expression of both proteins may have general implications for the activation of PPARgamma in alveolar macrophages.
Collapse
|
42
|
Baron RM, Carvajal IM, Fredenburgh LE, Liu X, Porrata Y, Cullivan ML, Haley KJ, Sonna LA, De Sanctis GT, Ingenito EP, Perrella MA. Nitric oxide synthase‐2 down‐regulates surfactant protein‐B expression and enhances endotoxin‐induced lung injury in mice. FASEB J 2004; 18:1276-8. [PMID: 15208261 DOI: 10.1096/fj.04-1518fje] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Acute respiratory distress syndrome (ARDS) is a life-threatening ailment characterized by severe lung injury involving inflammatory cell recruitment to the lung, cytokine production, surfactant dysfunction, and up-regulation of nitric oxide synthase 2 (NOS2) resulting in nitric oxide (NO) production. We hypothesized that NO production from NOS2 expressed in lung parenchymal cells in a murine model of ARDS would correlate with abnormal surfactant function and reduced surfactant protein-B (SP-B) expression. Pulmonary responses to nebulized endotoxin (lipopolysaccharide, LPS) were evaluated in wild-type (WT) mice, NOS2 null (-/-) mice, and NOS2-chimeric animals derived from bone marrow transplantation. NOS2-/- animals exhibited significantly less physiologic lung dysfunction and loss of SP-B expression than did WT animals. However, lung neutrophil recruitment and bronchoalveolar lavage cytokine levels did not significantly differ between NOS2-/- and WT animals. Chimeric animals for NOS2 exhibited the phenotype of the recipient and therefore demonstrated that parenchymal production of NOS2 is critical for the development of LPS-induced lung injury. Furthermore, administration of NO donors, independent of cytokine stimulation, decreased SP-B promoter activity and mRNA expression in mouse lung epithelial cells. This study demonstrates that expression of NOS2 in lung epithelial cells is critical for the development of lung injury and mediates surfactant dysfunction independent of NOS2 inflammatory cell expression and cytokine production.
Collapse
Affiliation(s)
- Rebecca M Baron
- Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Xiang Y, Zhang DW, Zhang JZH. Fully quantum mechanical energy optimization for protein-ligand structure. J Comput Chem 2004; 25:1431-7. [PMID: 15224387 DOI: 10.1002/jcc.20069] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
We present a quantum mechanical approach to study protein-ligand binding structure with application to a Adipocyte lipid-binding protein complexed with Propanoic Acid. The present approach employs a recently develop molecular fractionation with a conjugate caps (MFCC) method to compute protein-ligand interaction energy and performs energy optimization using the quasi-Newton method. The MFCC method enables us to compute fully quantum mechanical ab initio protein-ligand interaction energy and its gradients that are used in energy minimization. This quantum optimization approach is applied to study the Adipocyte lipid-binding protein complexed with Propanoic Acid system, a complex system consisting of a 2057-atom protein and a 10-atom ligand. The MFCC calculation is carried out at the Hartree-Fock level with a 3-21G basis set. The quantum optimized structure of this complex is in good agreement with the experimental crystal structure. The quantum energy calculation is implemented in a parallel program that dramatically speeds up the MFCC calculation for the protein-ligand system. Similarly good agreement between MFCC optimized structure and the experimental structure is also obtained for the streptavidin-biotin complex. Due to heavy computational cost, the quantum energy minimization is carried out in a six-dimensional space that corresponds to the rigid-body protein-ligand interaction.
Collapse
Affiliation(s)
- Yun Xiang
- Department of Chemistry, New York University, 100 Washington Square East, Room 1001, New York, New York 10003, USA
| | | | | |
Collapse
|
44
|
Sun L, Nicholson AC, Hajjar DP, Gotto AM, Han J. Adipogenic differentiating agents regulate expression of fatty acid binding protein and CD36 in the J744 macrophage cell line. J Lipid Res 2003; 44:1877-86. [PMID: 12867536 DOI: 10.1194/jlr.m300084-jlr200] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Adipocyte fatty acid binding protein (aP2) is a key mediator of intracellular transport and metabolism of fatty acids. Its expression during adipocyte differentiation is regulated through the actions of peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer binding protein alpha (C/EBPalpha). Macrophages also express aP2, and the lack of macrophage aP2 significantly reduces atherosclerotic lesion size in hypercholesterolemic mice. We investigated the regulation of expression of macrophage aP2 and CD36, a fatty acid membrane binding protein and scavenger receptor, in response to the adipogenic agents isobutylmethylxanthine (IBMX), insulin, and dexamethasone, a combination of agents shown to induce fibroblast-to-adipocyte differentiation. Treatment of J774 macrophages with adipogenic agents significantly induced aP2 mRNA expression, while CD36 expression was inhibited. Dexamethasone was essential and sufficient to induce aP2 expression, and insulin had a synergistic effect. However, IBMX antagonized induced-aP2 expression. aP2 protein expression and [14C]oleic acid uptake by macrophages were also increased by dexamethasone. Unlike what occurs in adipocytes, adipogenic agents had mixed effects on the expression of PPARgamma and C/EBPalpha in macrophages. Our data demonstrate differences in the regulation of aP2 in adipocytes and macrophages and show that macrophage aP2 expression by adipogenic agents is independent of the PPARgamma and/or C/EBPalpha signaling pathway.
Collapse
Affiliation(s)
- Li Sun
- Center of Vascular Biology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
| | | | | | | | | |
Collapse
|
45
|
Schoeffler AJ, Ruiz CR, Joubert AM, Yang X, LiCata VJ. Salt modulates the stability and lipid binding affinity of the adipocyte lipid-binding proteins. J Biol Chem 2003; 278:33268-75. [PMID: 12794068 DOI: 10.1074/jbc.m304955200] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Adipocyte lipid-binding protein (ALBP or aP2) is an intracellular fatty acid-binding protein that is found in adipocytes and macrophages and binds a large variety of intracellular lipids with high affinity. Although intracellular lipids are frequently charged, biochemical studies of lipid-binding proteins and their interactions often focus most heavily on the hydrophobic aspects of these proteins and their interactions. In this study, we have characterized the effects of KCl on the stability and lipid binding properties of ALBP. We find that added salt dramatically stabilizes ALBP, increasing its Delta G of unfolding by 3-5 kcal/mol. At 37 degrees C salt can more than double the stability of the protein. At the same time, salt inhibits the binding of the fluorescent lipid 1-anilinonaphthalene-8-sulfonate (ANS) to the protein and induces direct displacement of the lipid from the protein. Thermodynamic linkage analysis of the salt inhibition of ANS binding shows a nearly 1:1 reciprocal linkage: i.e. one ion is released from ALBP when ANS binds, and vice versa. Kinetic experiments show that salt reduces the rate of association between ANS and ALBP while simultaneously increasing the dissociation rate of ANS from the protein. We depict and discuss the thermodynamic linkages among stability, lipid binding, and salt effects for ALBP, including the use of these linkages to calculate the affinity of ANS for the denatured state of ALBP and its dependence on salt concentration. We also discuss the potential molecular origins and potential intracellular consequences of the demonstrated salt linkages to stability and lipid binding in ALBP.
Collapse
Affiliation(s)
- Allyn J Schoeffler
- Department of Biological Sciences, Louisiana State University, Baton Rouge, Louisiana 70803, USA
| | | | | | | | | |
Collapse
|
46
|
Jin X, Fukuda N, Su J, Takagi H, Lai Y, Lin Z, Kanmatsuse K, Wang ZW, Unger RH. Effects of leptin on endothelial function with OB-Rb gene transfer in Zucker fatty rats. Atherosclerosis 2003; 169:225-33. [PMID: 12921973 DOI: 10.1016/s0021-9150(03)00159-x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The metabolic syndrome in association with obesity is a major clinical problem inducing hypertension, diabetes mellitus, and atherosclerosis. Leptin induces angiogenesis by its proliferative effects on endothelial cells (ECs) via OB receptor (OB-Rb) gene. We evaluated the growth of ECs and intracellular signalings in response to leptin in vitro and the angiogenic effects of leptin in the cornea in vivo with and without adenovirus-mediated transfer of the OB-Rb gene in Zucker fatty (ZF) rats as a model for the metabolic syndrome. Recombinant adenovirus vector encoding rat OB-Rb (Ad.OB-Rb) or Escherichia coli. LacZ (Ad.LacZ) was transfected into cultured ECs from Zucker lean (ZL) rats and ZF rats. Leptin increased DNA synthesis dose-dependently in ECs from ZL rats but not ZF rats. Infection with Ad.OB-Rb, but not with Ad.LacZ, improved the growth effects of leptin in ECs from ZF rats. Leptin induced phosphorylation of Janus kinase (JAK)2, signal transducer and activator of transcription (STAT)3, and extracellular signal-regulated kinase (ERK) in ECs from ZL rats but not ZF rats. Infection with Ad.OB-Rb restored phosphorylation of JAK2 and STAT3 in ECs from ZF rats. Leptin induced angiogenesis in cornea from ZL rats, but not from ZF rats. Coadministration of leptin and Ad.OB-Rb induced angiogenesis in cornea from ZF rats. Ad.LacZ did not influence the angiogenic effects of leptin. The impaired endothelial function with the leptin resistance may be one of causes of the atherosclerosis in the metabolic syndrome.
Collapse
Affiliation(s)
- Xueqing Jin
- Second Department of Internal Medicine, Nihon University School of Medicine, Tokyo 173-8610, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abdelwahab SA, Owada Y, Kitanaka N, Iwasa H, Sakagami H, Kondo H. Localization of brain-type fatty acid-binding protein in Kupffer cells of mice and its transient decrease in response to lipopolysaccharide. Histochem Cell Biol 2003; 119:469-75. [PMID: 12802594 DOI: 10.1007/s00418-003-0538-z] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/06/2003] [Indexed: 01/16/2023]
Abstract
Brain-type fatty acid-binding protein (B-FABP) was localized in Kupffer cells of liver of postnatal day 10 (P10) and older mice in immunolight and electron microscopy as well as by in situ hybridization histochemistry. The immunoreaction products were localized in the cytoplasmic matrix but not within the nucleus. After peritoneal injection of lipopolysaccharide (LPS), the immunoreaction for B-FABP decreased markedly in Kupffer cells at 1 h postinjection and thereafter gradually recovered to the preinjection level by 24 h postinjection, although no decrease in the mRNA expression was detected in Northern blotting throughout the course after the injection. The specific localization of B-FABP, but not the other FABPs, in Kupffer cells, and its rapid decrease after LPS injection suggest the intimate involvement of B-FABP in Kupffer cells in the inflammatory reaction, probably through mediation of n-3 polyunsaturated fatty acids, which are strong binders of B-FABP.
Collapse
Affiliation(s)
- Soha Abdelkawi Abdelwahab
- Division of Histology, Department of Cell Biology, Graduate School of Medical Science, Tohoku University, 980-8575 Sendai, Japan
| | | | | | | | | | | |
Collapse
|
48
|
Haunerland NH, Spener F. Properties and physiological significance of fatty acid binding proteins. LIPOBIOLOGY 2003. [DOI: 10.1016/s1569-2558(03)33007-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
49
|
Davidson J, Rotondo D. Lipid metabolism. Curr Opin Lipidol 2002; 13:339-41. [PMID: 12045404 DOI: 10.1097/00041433-200206000-00015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
50
|
Abstract
Cytoplasmic fatty acid-binding proteins (FABPs) are a family of proteins, expressed in a tissue-specific manner, that bind fatty acid ligands and are involved in shuttling fatty acids to cellular compartments, modulating intracellular lipid metabolism, and regulating gene expression. Several members of the FABP family have been shown to have important roles in regulating metabolism and have links to the development of insulin resistance and the metabolic syndrome. Recent studies demonstrate a role for intestinal FABP in the control of dietary fatty acid absorption and chylomicron secretion. Heart FABP is essential for normal myocardial fatty acid oxidation and modulates fatty acid uptake in skeletal muscle. Liver FABP is directly involved in fatty acid ligand signaling to the nucleus and interacts with peroxisome proliferator-activated receptors in hepatocytes. The adipocyte FABP (aP2) has been shown to affect insulin sensitivity, lipid metabolism and lipolysis, and has recently been shown to play an important role in atherosclerosis. Interestingly, expression of aP2 by the macrophage promotes atherogenesis, thus providing a link between insulin resistance, intracellular fatty acid disposition, and foam cell formation. The FABPs are promising targets for the treatment of dyslipidemia, insulin resistance, and atherosclerosis in humans.
Collapse
Affiliation(s)
- Jeffrey B Boord
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232-6300, USA
| | | | | |
Collapse
|